Patent information
IP India · live recordAbstract
ABSTRACT IMMUNOGENIC POLYPEPTIDES AND VACCINE COMPOSITIONS AGAINST DIVERSE SARBECOVIRUSES The present disclosure relates to immunogenic polypeptides having Sarcebovirus 5 derived stabilized receptor binding domain (RBD) fragments. The immunogenic polypeptides comprise specific stabilizing mutations at various positions on the amino acid sequence. Further, the present invention also provides vaccine compositions comprising one or more of the immunogenic polypeptides, methods and uses thereof. 10
Applicants
2Inventors
3Claims
46Specification
Show full textCollapse
DESC:FIELD OF INVENTION
[001] The present disclosure broadly relates to the field of immunobiology, and particularly discloses immunogenic peptides, and vaccine compositions for 5 eliciting immune response against Sarbecoviruses. The present disclosure also relates to a method for producing the vaccine composition as well as the method of eliciting an immune response against diverse Sarbecoviruses, in a subject, by administering the subject with an effective amount of said vaccine composition. BACKGROUND OF THE INVENTION 10 [002] Coronaviruses (CoVs) have consistently posed a significant risk of dissemination. Zoonotic viruses such as betacoronaviruses continue to represent a global hazard through spillover events into human population. This has been witnessed multiple times in the last 30 years by severe acute respiratory syndrome coronavirus 1 (SARS CoV-1), Middle East respiratory syndrome 15 coronavirus (MERS CoV) outbreaks, and the latest severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) pandemic. The unprecedented appearance and spread of coronavirus disease of 2019 (COVID-19) at the global level accelerated the development of various vaccines utilizing multiple platforms, out of which some were approved by the regulatory agencies and rolled out for 20 public usage. However, the rapid evolution of SARS CoV-2 resulted in emergence of variants which exhibited immune escape and rendered the vaccines less effective (Li et al., 2024; Liu et al., 2024; Lyke et al., 2022).
[003] Sarbecoviruses are a subgenus of betacoronaviruses that includes the SARS- CoV, MERS-CoV, and the more recently identified SARS-CoV-2, which causes 25 COVID-19. In Sarbecoviruses such as SARS CoV-1 and SARS CoV-2, the viral spike protein (S) is the principal target of neutralising antibodies that prevent infection. Within spike, the immunodominant receptor-binding domain (RBD) is the primary target of neutralising antibodies as observed in COVID-19 convalescent sera and vaccine recipients (Premkumar et al., 2020; Yang et al., 30 2020). 2
[004] The attachment and entry of the viral particles into host cells is facilitated by the S-proteins through their binding to ACE2 (angiotensin-converting enzyme-2). Protein S is comprised of two distinct subunits, namely S1 and S2. The S1 subunit, positioned in the N-terminal region, encompasses RBD responsible for 5 recognizing the host cell receptor (Huang et al., 2020; Lan et al., 2020). The RBDs of SARS-CoV-2, SARS CoV-1 as well as MERS CoV have been demonstrated to be highly suitable targets for the development of vaccines across various platforms owing to their exceptional level of antigenicity and capability to effectively stimulate robust immune responses (Ahmed et al., 2021; Malladi, Patel, et al., 10 2021; Tai et al., 2020, 2023).
[005] Human infection with viruses against which pre-existing immunity is not prevalent in the population can result in epidemics and even pandemics with substantial morbidity and mortality. These outbreaks can have a negative influence on public health and the economy worldwide. Considering the number of viruses 15 which have various zoonotic reservoirs and the potential to infect humans, future pandemic preparedness is of utmost importance to mitigate these risks.
[006] Therefore, there remains a dire need for the development of a comprehensive thermostable, safe and effective pan-sarbecovirus vaccine formulation, which can elicit a targeted immune response and is also capable of eliciting a broadly 20 neutralizing cross reactive response against diverse Sarbecoviruses. SUMMARY OF INVENTION
[007] In an aspect of the present disclosure, there is provided an immunogenic polypeptide comprising a polypeptide selected from the group consisting of: a 25 polypeptide having an amino acid sequence of at least 95% sequence identity to the sequence selected from SEQ ID NO: 1 or SEQ ID NO: 59; a polypeptide having an amino acid sequence of at least 95% sequence identity to the sequence selected from SEQ ID NO: 3 or SEQ ID NO: 61; a polypeptide having an amino acid sequence of at least 95% sequence identity to the sequence selected from SEQ 30 ID NO: 5 or SEQ ID NO: 63; a polypeptide having an amino acid sequence of at least 95% sequence identity to the sequence selected from SEQ ID NO: 7 or SEQ 3 ID NO: 65; a polypeptide having an amino acid sequence of at least 95% sequence identity to the sequence selected from SEQ ID NO: 9 or SEQ ID NO: 67, and a polypeptide having an amino acid sequence of at least 95% sequence identity to the sequence selected from SEQ ID NO: 85 or SEQ ID NO: 69, wherein the 5 polypeptide comprises substitution mutations A17P, Y34W, and P196L.
[008] In an aspect of the present disclosure, there is provided a polynucleotide encoding the immunogenic polypeptide as described herein.
[009] In another aspect of the present disclosure, there is provided a recombinant vector containing the polynucleotide as disclosed herein operably linked to a 10 promoter.
[0010] In another aspect of the present disclosure, there is provided a recombinant host cell comprising the recombinant vector as described herein.
[0011] In another aspect of the present disclosure, there is provided a vaccine composition comprising the immunogenic polypeptide as disclosed herein, and a 15 pharmaceutically acceptable carrier.
[0012] In an aspect of the present disclosure, there is provided a method for producing the vaccine composition comprising: (a) culturing the recombinant host cell as described herein, under suitable conditions to obtain the immunogenic polypeptide; (b) subjecting the immunogenic polypeptide to purification; and (c) 20 contacting the immunogenic polypeptide of step (b) with a pharmaceutically acceptable carrier, to obtain the vaccine composition.
[0013] In an aspect of the present disclosure, there is provided a method of eliciting an immune response against diverse Sarbecoviruses, in a subject, comprising administering the subject with an effective amount of the vaccine 25 composition as disclosed herein.
[0014] In an aspect of the present disclosure, there is provided a kit comprising the immunogenic polypeptide or the vaccine composition as described herein, and an instruction leaflet.
[0015] These and other features, aspects, and advantages of the present 30 subject matter will be better understood with reference to the following description and appended claims. This summary is provided to introduce a selection of 4 concepts in a simplified form. This summary is not intended to identify key features or essential features of the claimed subject matter, nor is it intended to be used to limit the scope of the claimed subject matter. BRIEF DESCRIPTION OF ACCOMPANYING DRAWINGS 5
[0016] The following drawings form a part of the present specification and are included to further illustrate aspects of the present disclosure. The disclosure may be better understood by reference to the drawings in combination with the detailed description of the specific embodiments presented herein. 10 [0017] Figure 1 depicts the results related to expression and purification of Sarbecoviruses RBD derivatives. Coomassie stained profiles of Sarbecoviruses RBDs purified from Expi293F cells are shown, in accordance with the embodiments herein.
[0018] Figure 2 depicts relative thermal stability of Sarbecoviruses RBD 15 derivatives: Nano-DSF profiles showing thermal melting temperature for Sarbecoviruses RBD derivatives: wild type (WT) and stabilized (St), in accordance with the embodiments herein.
[0019] Figure 3 depicts relative thermal tolerance of Sarbecoviruses RBD derivatives: Purified proteins were incubated at temperatures ranging from 4-70?C 20 for 2 hours followed by Nano-DSF profiles of (A) wild type and (B) stabilized RBD derivatives, in accordance with the embodiments herein.
[0020] Figure 4 depicts immunogenicity studies in mice: Endpoint ELISA IgG titers against different Sarbecoviruses RBDs obtained after two immunizations with (A) individual stabilized RBD oligomers and (B) stabilized 25 RBD derivative cocktail formulated with adjuvant, in accordance with the embodiments herein.
[0021] Figure 5 depicts immunogenicity studies in mice: Pseudovirus neutralization titers against (A) SARS CoV-1, (B) SARS CoV-2, (C) BtKY72 and (D) heterologous pseudoviruses including LYRa3, SHC014 and Khosta-2 from 30 sera obtained after two immunizations, in accordance with the embodiments herein. 5
[0022] Figure 6 illustrates efficacy of Stabilized RBD trimer and RBD-S2 monomer cocktail formulation, wherein A) is a schematic representation of the immunization protocol, and (B) depicts body weight change and lung viral titres in mice post SARS-CoV-1 challenge and (C) depicts body weight change and 5 lung viral titres in mice post SARS-CoV-2 BA.5 challenge, in accordance with the embodiments herein.
[0023] Figure 6 illustrates long-term thermal stability of the RBD cocktail immunogens wherein (A) depicts thermal denaturation profile and (B) depicts binding affinity of the RBD cocktail immunogens from day0- day 30 for proteins 10 incubated at 4°C and 37°C determined by Nano-DSF and BLI experiments respectively. Lyophilized proteins were incubated at the indicated temperatures and reconstituted in PBS prior to measurements, in accordance with the embodiments herein. 15 DETAILED DESCRIPTION OF THE INVENTION
[0024] Those skilled in the art will be aware that the present disclosure is subject to variations and modifications other than those specifically described. It is to be understood that the scope of the present disclosure includes all such 20 variations and modifications that may be apparent to a person skilled in the art in light of the present disclosure. The disclosure also includes all such steps, features, compositions, and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any or more of such steps or features. 25 Definitions
[0025] For convenience, before further description of the present disclosure, certain terms employed in the specification, and examples are delineated here. These definitions should be read in the light of the remainder of the disclosure and understood as by a person of skill in the art. The terms used herein have the 30 meanings recognized and known to those of skill in the art, however, for 6 convenience and completeness, particular terms and their meanings are set forth below.
[0026] The articles “a”, “an” and “the” are used to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. 5 [0027] The terms “comprise” and “comprising” are used in the inclusive, open sense, meaning that additional elements may be included. It is not intended to be construed as “consists of only”.
[0028] Throughout this specification, unless the context requires otherwise the word “comprise”, and variations such as “comprises” and “comprising”, will 10 be understood to imply the inclusion of a stated element or step or group of element or steps but not the exclusion of any other element or step or group of element or steps.
[0029] The term “including” is used to mean “including but not limited to”. “Including” and “including but not limited to” are used interchangeably. 15 [0030] The term “pharmaceutically acceptable carrier” refers to any known carriers, excipients, adjuvants known to a person skilled in the art, which can be used in therapeutic and vaccine formulations. The term “pharmaceutically effective amount” or “effective amount”, as used herein, refers to an amount that is effective in eliciting an immune response, in a subject. 20 [0031] The term “vaccine composition” refers to a composition that elicits a prophylactic or therapeutic immune response in a subject. Typically, a vaccine composition elicits an antigen-specific immune response to an antigen of a pathogen, for example a viral pathogen, or to a cellular constituent correlated with a pathological condition. 25 [0032] The term “subject” refers to any animal, including a mammal, e.g., human and non-human mammals. Examples of non-human animals include non-human primates, dogs, cats, cattle, horses, sheep, pigs, goats, rabbits, mice, rats, hamsters, guinea pigs and etc. Unless otherwise noted, the terms “patient” or “subject” are used herein interchangeably. Preferably, the subject is human. 30 [0033] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill 7 in the art to which this disclosure belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the disclosure, the preferred methods, and materials are now described. All publications mentioned herein are incorporated herein by reference. 5 [0034] Embodiments herein provide immunogenic polypeptides having Sarcebovirus derived stabilized receptor binding domain (RBD) fragments. The wildtype RBD fragments obtained from various Sarbecoviruses, particularly SARS-CoV-1 (Clade 1a), WIV-1 (Clade 1a), RaTG13 (Clade 1b), RmYN02 (Clade 2), BtKY72 (Clade 3), and SARS CoV-2 XBB1.5 are stabilized by 10 introducing specific stabilizing mutations at various positions on the amino acid sequence. The present inventors observed that the introduction of these mutations substantially improved thermal stability by about ~7°C, and enhanced purified yield by about 3-23-fold, relative to corresponding wildtype (WT) RBDs, without affecting their binding to conformation specific ligands. 15 [0035] Further, in some embodiments, the immunogenic polypeptides comprise Sarbecovirus derived stabilized receptor binding domain (RBD) fragment, and a fragment of S2 subunit of SARS-CoV-2 spike protein . The fragment of S2 subunit may be attached N-terminally or C-terminally to the stabilized RBD, preferably via a linker. In an embodiment, the fragment of S2 20 subunit is attached C-terminally to the stabilized RBD. The fragment of S2 subunit of SARS-CoV-2 spike protein may be engineered to include substitution mutations at positions 817, 892, 899, 942, 969 and 973, positions in respect of the wildtype S2 subunit of SARS-CoV-2 spike protein (Accession Id: YP_009724390.1). In an embodiment, the amino acid sequence of the fragment of S2 subunit of SARS- 25 CoV-2 spike protein is engineered to substitute amino acid residue at positions 817, 892, 899, and 942 with proline (i.e. F817P, A892P, A899P, and A942P respectively) and substitute amino acid residue at positions 969 and 973 with aspartic acid (i.e. N969D and I973D respectively). In an embodiment, the fragment of S2 subunit of SARS-CoV-2 spike protein has an amino acid sequence 30 as depicted in SEQ ID NO: 83 (corresponding nucleotide sequence is depicted in SEQ ID NO: 84). 8
[0036] In an embodiment, the stabilized RBD fragments obtained from Sarbecoviruses: SARS-CoV-1 (Clade 1a), WIV-1 (Clade 1a), RaTG13 (Clade 1b), RmYN02 (Clade 2), BtKY72 (Clade 3), and SARS CoV-2 XBB1.5 are depicted in SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, 5 and SEQ ID NO: 85, respectively.
[0037] In an embodiment, the polypeptides having a combination of sarbecovirus derived stabilized receptor binding domain (RBD) fragment, and a fragment of S2 subunit of SARS-CoV-2 spike protein: Stabilized SARS CoV-1 RBD-S2, Stabilized WIV-1 RBD-S2, Stabilized RaTG13 RBD-S2, Stabilized 10 RmYN02 RBD-S2, Stabilized BtKY72 RBD-S2, and Stabilized SARS CoV-2 XBB1.5 RBD-S2 are depicted in SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID NO: 67, and SEQ ID NO: 69, respectively.
[0038] Substitution mutations and stabilizing mutations, according to embodiments herein, are also described herein by use of the following notation: 15 amino acid residue substituted: amino acid position in the sequence: amino acid residue substitute. Accordingly, an amino acid substitution with, for instance, if the amino acid substitution is of phenylalanine (F) with proline (P), at position 111 in a sequence, it may be indicated as F111P. Further, alternative amino acid residues substitutes are represented by the notation: amino acid substitute/ amino 20 acid substitute/ amino acid substitute. For instance, if amino acid substitution of phenylalanine (F) is with proline (P) or serine (S), at position 111 in a sequence, it may be indicated as F111P/S. Similarly, when more than one alternatives are possible, it may be indicated as F111P/S/A, and so on. In general, when more than one alternatives amino acid residues are possible at a position, it may be indicated 25 as P/S which is intended to mean that any of proline or serine may be present at that position Similarly, N/I may indicate that any of asparagine or isoleucine may be present at that position, and so on. Such notations are generally known to a person skilled in the art and generally used in representing amino acid residues/substitutions in a given amino acid sequence. Also, amino acids are 30 generally represented by single letter and three letter abbreviations, for example “Alanine” is represented by single letter code “A” and three letter code “ala” or 9 “Ala”. Similarly, the single letter code include R (Arginine), N (Asparagine), D (Aspartic acid), C (Cysteine), E (Glutamic acid), Q (Glutamine), G (Glycine), H (Histidine), I (Isoleucine), L (Leucine), K (Lysine), M (Methionine), F (Phenylalanine), P (Proline), S (Serine), T (Threonine), W (Tryptophan), Y 5 (Tyrosine), and V (Valine). Such representations are generally used and well understood by a person skilled in the art. The present disclosure in describing the present invention employs such representations or phrases which is intended to mean the generally acceptable meaning in the art.
[0039] Embodiments herein also provide vaccine compositions comprising 10 one or more of the immunogenic polypeptides as described herein. It has been observed by the present inventors that a cocktail formulation comprising two or more of the immunogenic polypeptides as described herein significantly augments the yield, thermostability, and immunogenicity of the RBD fragments. The present disclosure provides stabilization of RBD fragments obtained from different clades 15 of Sarbecoviruses, which is combined to achieve a pan-Sarbecoviruses vaccine formulation.
[0040] The immunogenic polypeptides, according to embodiments herein, are resistant to 2-hour incubation at temperatures of up to 60? in PBS, in contrast to corresponding WT RBDs. Further, lyophilized cocktail formulations, according 20 to embodiments herein, retained antigenicity even after storage at 37°C for over 15 days. In an embodiment, the vaccine composition is a lyophilized composition. Immunogenic polypeptide
[0041] Embodiments herein provide immunogenic polypeptides. In an embodiment, the immunogenic polypeptide comprises a polypeptide having an 25 amino acid sequence of at least 95% sequence identity to the sequence selected from SEQ ID NO: 1 or SEQ ID NO: 59, wherein the polypeptide comprises substitution mutations Y34W and P195L. In an embodiment of the present disclosure, the identity is at least 95%, 96%, 97%, 98%, 99%, or 99.5% to the amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 59. In another 30 embodiment of the present disclosure, the immunogenic polypeptide comprising a 10 polypeptide having an amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 59.
[0042] In an embodiment of the present disclosure, there is provided an immunogenic polypeptide comprising a polypeptide having an amino acid 5 sequence of at least 95% sequence identity to the sequence selected from SEQ ID NO: 3 or SEQ ID NO: 61, wherein the polypeptide comprises substitution mutations Y34W and P195L. In another embodiment of the present disclosure, the identity is at least 95%, 96%, 97%, 98%, 99%, 99.5% to the amino acid sequence as set forth in SEQ ID NO: 3or SEQ ID NO: 61. In an embodiment of the present 10 disclosure, there is provided an immunogenic polypeptide comprising a polypeptide having an amino acid sequence as set forth in SEQ ID NO: 3 or SEQ ID NO: 61.
[0043] In an embodiment of the present disclosure, there is provided an immunogenic polypeptide comprising a polypeptide having an amino acid 15 sequence of at least 95% sequence identity to the sequence selected from SEQ ID NO: 5 or SEQ ID NO: 63, wherein the polypeptide comprises substitution mutations A17P, Y34W, and P196L. In another embodiment of the present disclosure, the identity is at least 95%, 97%, 98%, 99%, 99.5% to the amino acid sequence as set forth in SEQ ID NO: 5 or SEQ ID NO: 63. In an embodiment of 20 the present disclosure, there is provided an immunogenic polypeptide comprising a polypeptide having an amino acid sequence as set forth in SEQ ID NO: 5 or SEQ ID NO: 63.
[0044] In an embodiment of the present disclosure, there is provided an immunogenic polypeptide comprising a polypeptide having an amino acid 25 sequence of at least 95% sequence identity to the sequence selected from SEQ ID NO: 7 or SEQ ID NO: 65, wherein the polypeptide comprises substitution mutations Y34W and P177L. In another embodiment of the present disclosure, the identity is at least 95%, 96%, 97%, 98%, 99%, 99.5% to the amino acid sequence selected from SEQ ID NO: 7 or SEQ ID NO: 65. In an embodiment of the present 30 disclosure, there is provided an immunogenic polypeptide comprising a 11 polypeptide having an amino acid sequence as set forth in SEQ ID NO: 7 or SEQ ID NO: 65.
[0045] In an embodiment of the present disclosure, there is provided an immunogenic polypeptide comprising a polypeptide having an amino acid 5 sequence of at least 95% sequence identity to the sequence selected from SEQ ID NO: 9 or SEQ ID NO: 67, wherein the polypeptide comprises substitution mutations Y34W and P195L. In another embodiment of the present disclosure, the identity is at least 95%, 96%, 97%, 98%, 99%, 99.5% to the amino acid sequence selected from SEQ ID NO: 9 or SEQ ID NO: 67. In an embodiment of the present 10 disclosure, there is provided an immunogenic polypeptide comprising a polypeptide having an amino acid sequence selected from SEQ ID NO: 9 or SEQ ID NO: 67.
[0046] In an embodiment of the present disclosure, there is provided an immunogenic polypeptide comprising a polypeptide having an amino acid 15 sequence of at least 95% sequence identity to the sequence as set forth in SEQ ID NO: 85 or SEQ ID NO: 69, wherein the polypeptide comprises substitution mutations A17P, Y34W, and P196L. In another embodiment of the present disclosure, the identity is at least 95%, 96%, 97%, 98%, 99%, 99.5% to the amino acid sequence selected from SEQ ID NO: 85 or SEQ ID NO: 69. In an embodiment 20 of the present disclosure, there is provided an immunogenic polypeptide comprising a polypeptide having an amino acid sequence selected from SEQ ID NO: 85 or SEQ ID NO: 69.
[0047] In an embodiment of the present disclosure, there is provided an immunogenic polypeptide comprising a polypeptide having an amino acid 25 sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID NO: 67, and SEQ ID NO: 69. Full length Immunogenic polypeptide
[0048] The immunogenic polypeptide, according to embodiments herein, 30 may further comprise one or more peptides such as TPA signal sequence, oligomerization domain, His-tag, etc. In an embodiment, there is provided an 12 immunogenic polypeptide comprising a polypeptide having at least 95% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID NO: 67, and 5 SEQ ID NO: 69, wherein the immunogenic polypeptide further comprises a peptide selected from TPA signal peptide; oligomerization domain; HRV3C protease cleavage site or a portion thereof; His tag; one or more linkers; or combinations thereof.
[0049] In an embodiment, there is provided an immunogenic polypeptide 10 comprising a polypeptide having at least 95% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID NO: 67, and SEQ ID NO: 69, wherein the polypeptide is further attached to a oligomerization domain, preferably via a 15 linker.
[0050] Various oligomerization domains are known and may be used in embodiments herein. Examples of oligomerization domains includes human cartilage matrix protein (hCMP), chicken CMP (cCMP), fish cartilage matrix protein (F1CMP), fish isoform 2 cartilage matrix protein (F2-CMP), leucine 20 Zipper with double cysteine (CCIZ), Synthetic oligomerization domain (cCMP- IZm), foldon, or glycosylated leucine zipper sequence (Gly IZ). In an embodiment, the oligomerization domain is a synthetic oligomerization domain (cCMP-IZm) having an amino acid sequence as set forth in SEQ ID NO. 38.
[0051] In an embodiment, there is provided an immunogenic polypeptide 25 comprising a polypeptide having at least 95% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID NO: 67, and SEQ ID NO: 69, wherein the polypeptide is further attached, at the N-terminal end, to a TPA signal peptide 30 having an amino acid sequence as set forth in SEQ ID NO. 36. 13
[0052] In an embodiment, there is provided an immunogenic polypeptide comprising a polypeptide having at least 95% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 59, SEQ ID NO: 61, 5 SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID NO: 67, and SEQ ID NO: 69, wherein the polypeptide is further attached at the C-terminal end to a HRV3C protease cleavage site having an amino acid sequence as set forth in SEQ ID NO. 40.
[0053] The TPA signal peptide; oligomerization domain; HRV3C protease cleavage site or a portion thereof; and/or the His tag, may be attached to the 10 polypeptide having at least 95% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID NO: 67, and SEQ ID NO: 69 by one or more linkers.
[0054] Various linkers are known and may be used in embodiments herein. 15 In an embodiment, the linker is having an amino acid sequence selected from “AAS”, “S”, “AS”, “GT”, "GSAGS" (SEQ ID NO.52), "ASSEGTMMRGELKN"(SEQ ID NO.53), and/or "GS".
[0055] In an embodiment, the immunogenic polypeptide further comprises a peptide “EIS” attached at the N-terminal end. The peptide “EIS” is a vector 20 derived peptide and is attached to the N-terminal end of the immunogenic polypeptide. In an embodiment, the immunogenic polypeptide comprises TPA signal peptide at the N-terminal end of the immunogenic polypeptide attached by the peptide “EIS”.
[0056] In an embodiment, the immunogenic polypeptide comprises 25 a polypeptide having an amino acid sequence as set forth in SEQ ID NO: 1 attached to a oligomerization domain at C-terminal end of the polypeptide by a linker “GS”, wherein the oligomerization domain is further attached to a HRV3C protease cleavage site by a linker “AAS” followed by a His-tag using a linker “S”, wherein the polypeptide is attached to a peptide of sequence “EIS” at the N- 30 terminal end which is attached to TPA signal peptide, wherein the oligomerization domain has an amino acid sequence as set forth in SEQ ID NO. 38. In an 14 embodiment of the present disclosure, there is provided an immunogenic peptide comprising a polypeptide having an amino acid sequence of at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% sequence identity to a sequence as set forth in SEQ ID NO: 13, wherein the polypeptide comprises 5 substitution mutations Y60W and P221L. In an embodiment of the present disclosure, there is provided an immunogenic peptide comprising a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 13.
[0057] In an embodiment, the immunogenic polypeptide comprises 10 a polypeptide having an amino acid sequence as set forth in SEQ ID NO: 1 attached to a oligomerization domain at C-terminal end of the polypeptide by a linker “GS”, wherein the oligomerization domain is further attached to a HRV3C protease cleavage site by a linker “AAS”, wherein the polypeptide is attached to a peptide of sequence “EIS” at the N-terminal end, wherein the oligomerization 15 domain has an amino acid sequence as set forth in SEQ ID NO. 38. In an embodiment of the present disclosure, there is provided an immunogenic peptide comprising a polypeptide having an amino acid sequence of at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% sequence identity to a sequence as set forth in SEQ ID NO: 15, wherein the polypeptide comprises 20 substitution mutations Y37W and P198L. In an embodiment of the present disclosure, there is provided an immunogenic peptide comprising a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 15.
[0058] In an embodiment, the immunogenic polypeptide comprises 25 a polypeptide having an amino acid sequence as set forth in SEQ ID NO: 3 attached to a oligomerization domain at C-terminal end of the polypeptide by a linker “AS”, wherein the oligomerization domain is further attached to a HRV3C protease cleavage site by a linker “GT” followed by a His-tag using a linker “S”, wherein the polypeptide is attached to a peptide of sequence “EIS” at the N- 30 terminal end which is attached to TPA signal peptide, wherein the oligomerization domain has an amino acid sequence as set forth in SEQ ID NO. 38. In an 15 embodiment of the present disclosure, there is provided an immunogenic peptide comprising a polypeptide having an amino acid sequence of at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% sequence identity to a sequence as set forth in SEQ ID NO: 18, wherein the polypeptide comprises 5 substitution mutations Y60W and P221L. In an embodiment of the present disclosure, there is provided an immunogenic peptide comprising a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 18.
[0059] In an embodiment, the immunogenic polypeptide comprises 10 a polypeptide having an amino acid sequence as set forth in SEQ ID NO: 3 attached to a oligomerization domain at C-terminal end of the polypeptide by a linker “AS”, wherein the oligomerization domain is further attached to a HRV3C protease cleavage site by a linker “GT”, wherein the polypeptide is attached to a peptide of sequence “EIS” at the N-terminal end which is attached to TPA signal 15 peptide, wherein the oligomerization domain has an amino acid sequence as set forth in SEQ ID NO. 38. In an embodiment of the present disclosure, there is provided an immunogenic peptide comprising a polypeptide having an amino acid sequence of at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% sequence identity to a sequence as set forth in SEQ ID NO: 20, 20 wherein the polypeptide comprises substitution mutations Y37W and P198L. In an embodiment of the present disclosure, there is provided an immunogenic peptide comprising a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 20.
[0060] In an embodiment, the immunogenic polypeptide comprises 25 a polypeptide having an amino acid sequence as set forth in SEQ ID NO: 5 attached to a oligomerization domain at C-terminal end of the polypeptide by a linker “AS”, wherein the oligomerization domain is further attached to a HRV3C protease cleavage site by a linker “GT” followed by a His-tag using a linker “S”, wherein the polypeptide is attached to a peptide of sequence “EIS” at the N- 30 terminal end which is attached to TPA signal peptide, wherein the oligomerization domain has an amino acid sequence as set forth in SEQ ID NO. 38. In an 16 embodiment of the present disclosure, there is provided an immunogenic peptide comprising a polypeptide having an amino acid sequence of at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% sequence identity to a sequence as set forth in SEQ ID NO: 23, wherein the polypeptide comprises 5 substitution mutations A43P, Y60W, and P222L. In an embodiment of the present disclosure, there is provided an immunogenic peptide comprising a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 23.
[0061] In an embodiment, the immunogenic polypeptide comprises 10 a polypeptide having an amino acid sequence as set forth in SEQ ID NO: 5 attached to a oligomerization domain at C-terminal end of the polypeptide by a linker “AS”, wherein the oligomerization domain is further attached to a HRV3C protease cleavage site by a linker “GT”, wherein the polypeptide is attached to a peptide of sequence “EIS” at the N-terminal end which is attached to TPA signal 15 peptide, wherein the oligomerization domain has an amino acid sequence as set forth in SEQ ID NO. 38. In an embodiment of the present disclosure, there is provided an immunogenic peptide comprising a polypeptide having an amino acid sequence of at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% sequence identity to a sequence as set forth in SEQ ID NO: 25, 20 wherein the polypeptide comprises substitution mutations A20P, Y37W and P199L. In an embodiment of the present disclosure, there is provided an immunogenic peptide comprising a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 25.
[0062] In an embodiment, the immunogenic polypeptide comprises 25 a polypeptide having an amino acid sequence as set forth in SEQ ID NO: 7 attached to a oligomerization domain at C-terminal end of the polypeptide by a linker “AS”, wherein the oligomerization domain is further attached to a HRV3C protease cleavage site by a linker “GT” followed by a His-tag using a linker “S”, wherein the polypeptide is attached to a peptide of sequence “EIS” at the N- 30 terminal end which is attached to TPA signal peptide, wherein the oligomerization domain has an amino acid sequence as set forth in SEQ ID NO. 38. In an 17 embodiment of the present disclosure, there is provided an immunogenic peptide comprising a polypeptide having an amino acid sequence of at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% sequence identity to a sequence as set forth in SEQ ID NO: 28, wherein the polypeptide comprises 5 substitution mutations Y60W and P203L. In an embodiment of the present disclosure, there is provided an immunogenic peptide comprising a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 28.
[0063] In an embodiment, the immunogenic polypeptide comprises 10 a polypeptide having an amino acid sequence as set forth in SEQ ID NO: 7 attached to a oligomerization domain at C-terminal end of the polypeptide by a linker “AS”, wherein the oligomerization domain is further attached to a HRV3C protease cleavage site by a linker “GT”, wherein the polypeptide is attached to a peptide of sequence “EIS” at the N-terminal end which is attached to TPA signal 15 peptide, wherein the oligomerization domain has an amino acid sequence as set forth in SEQ ID NO. 38. In an embodiment of the present disclosure, there is provided an immunogenic peptide comprising a polypeptide having an amino acid sequence of at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% sequence identity to a sequence as set forth in SEQ ID NO: 30, 20 wherein the polypeptide comprises substitution mutations Y37W and P180L. In an embodiment of the present disclosure, there is provided an immunogenic peptide comprising a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 30.
[0064] In an embodiment, the immunogenic polypeptide comprises 25 a polypeptide having an amino acid sequence as set forth in SEQ ID NO: 9 attached to a oligomerization domain at C-terminal end of the polypeptide by a linker “AS”, wherein the oligomerization domain is further attached to a HRV3C protease cleavage site by a linker “GT” followed by a His-tag using a linker “S”, wherein the polypeptide is attached to a peptide of sequence “EIS” at the N- 30 terminal end which is attached to TPA signal peptide, wherein the oligomerization domain has an amino acid sequence as set forth in SEQID NO. 38. In an 18 embodiment of the present disclosure, there is provided an immunogenic peptide comprising a polypeptide having an amino acid sequence of at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% sequence identity to a sequence as set forth in SEQ ID NO: 33, wherein the polypeptide comprises 5 substitution mutations Y60W, and P221L. In an embodiment of the present disclosure, there is provided an immunogenic peptide comprising a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 33.
[0065] In an embodiment, the immunogenic polypeptide comprises 10 a polypeptide having an amino acid sequence as set forth in SEQ ID NO: 9 attached to a oligomerization domain at C-terminal end of the polypeptide by a linker “AS”, wherein the oligomerization domain is further attached to a HRV3C protease cleavage site by a linker “GT”, wherein the polypeptide is attached to a peptide of sequence “EIS” at the N-terminal end which is attached to TPA signal 15 peptide, wherein the oligomerization domain has an amino acid sequence as set forth in SEQID NO. 38. In an embodiment of the present disclosure, there is provided an immunogenic peptide comprising a polypeptide having an amino acid sequence of at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% sequence identity to a sequence as set forth in SEQ ID NO: 35, 20 wherein the polypeptide comprises substitution mutations Y37W and P198L. In an embodiment of the present disclosure, there is provided an immunogenic peptide comprising a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 35.
[0066] In an embodiment of the present disclosure, there is provided an 25 immunogenic peptide comprising a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 71, SEQ ID NO: 73, SEQ ID NO: 75, SEQ ID NO: 77, SEQ ID NO: 79, and SEQ ID NO: 81. 30 [0067] In an embodiment, there is provided a polynucleotide encoding the immunogenic polypeptide as described herein. 19
[0068] In another embodiment, the polynucleotide has a nucleotide sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 14, SEQ ID NO: 19, SEQ ID NO: 24, SEQ ID NO: 29, SEQ ID NO: 34, SEQ ID NO: 60, SEQ ID NO: 62, SEQ ID 5 NO: 64, SEQ ID NO: 66, SEQ ID NO: 68, SEQ ID NO: 70, SEQ ID NO: 72, SEQ ID NO: 74, SEQ ID NO: 76, SEQ ID NO: 78, SEQ ID NO: 80, and SEQ ID NO: 82. The polynucleotide may be deoxy ribose nucleic acid (DNA) or ribose nucleic acid (RNA). In an embodiment, the polynucleotide is selected from DNA, RNA, or messenger RNA (mRNA). 10 [0069] In an embodiment, there is provided a recombinant vector containing the polynucleotide as disclosed herein, operably linked to a promoter.
[0070] In an embodiment, there is provided a recombinant host cell comprising the recombinant vector as described herein. The host cell is a bacterial cell, yeast cell, insect cell, or mammalian cell. The bacterial cell is Escherichia 15 coli, and the yeast cell is selected from the group consisting of Pichia X33, Pichia GlycoSwitch® , DSMZ 70382, GS115, KM71, KM71H, BG09, GS190, GS200, JC220, JC254, JC227, JC300-JC308, YJN165, and CBS7435, and wherein the insect cell is selected from the group consisting of Expi-Sf9®, Sf9, High Five® , Sf21, and S2, and wherein the mammalian cell is selected from the group consisting 20 of Expi293F®Expi-CHO-S ® , CHO-K1, CHO-S, HEK293F® , CHOBC™, SLIM™ , SPOT™ , SP2/0 , Sp2/0- Ag14, CHO DG44, HEK 293S, HEK 293 Gnt1- /- ,HEK293-EBNA1, CHOL-NSO, and NSO. Further, the host cell may be selected from OPENPichia (NCYC 2543 hoc1tr), OPENPichia his4, NCYC 2543 type strain, OPENPichia pep4, OPENPichia yps1, OPENPichia pep4 yps1, and 25 OPENPichia mutS strains.
[0071] Embodiments herein provide vaccine compositions. In an embodiment, there is provided a vaccine composition comprising the immunogenic polypeptide as described herein, and a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier is an adjuvant selected from an 30 oil-in-water adjuvant, a polymer and water adjuvant, a water-in-oil adjuvant, an aluminum hydroxide adjuvant, and combinations thereof. 20
[0072] In an exemplary embodiment of the present disclosure, the pharmaceutically acceptable carrier is selected from the group consisting of alhydrogel (aluminium hydroxide adjuvant), Alhydrogel CpG, Addavax (oil-in-water adjuvant), SWE (squalene-in-water emulsion adjuvant), and MF59. 5 [0073] In an embodiment, the vaccine composition comprises an immunogenic polypeptide of amino acid sequence of at least 95% sequence identity to amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 23, SEQ ID 10 NO: 25, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID NO: 67, SEQ ID NO: 69, SEQ ID NO: 71, SEQ ID NO: 73, SEQ ID NO: 75, SEQ ID NO: 77, SEQ ID NO: 79, and SEQ ID NO: 81. In an embodiment, the vaccine composition comprises an immunogenic polypeptide of amino acid sequence of 15 amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID NO: 67, SEQ ID 20 NO: 69, SEQ ID NO: 71, SEQ ID NO: 73, SEQ ID NO: 75, SEQ ID NO: 77, SEQ ID NO: 79, and SEQ ID NO: 81.
[0074] In an embodiment, the vaccine composition comprises an immunogenic polypeptide of amino acid sequence of at least 95% sequence identity to amino acid sequence selected from the group consisting of SEQ ID NO: 25 15, SEQ ID NO: 20, SEQ ID NO: 25, SEQ ID NO: 30, SEQ ID NO: 35, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID NO: 67, SEQ ID NO: 69, SEQ ID NO: 71, SEQ ID NO: 73, SEQ ID NO: 75, SEQ ID NO: 77, SEQ ID NO: 79, and SEQ ID NO: 81. In an embodiment, the vaccine composition comprises an immunogenic polypeptide of amino acid sequence of amino acid 30 sequence selected from the group consisting of SEQ ID NO: 15, SEQ ID NO: 20, SEQ ID NO: 25, SEQ ID NO: 30, SEQ ID NO: 35, SEQ ID NO: 59, SEQ ID NO: 21 61, SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID NO: 67, SEQ ID NO: 69, SEQ ID NO: 71, SEQ ID NO: 73, SEQ ID NO: 75, SEQ ID NO: 77, SEQ ID NO: 79, and SEQ ID NO: 81.
[0075] In another embodiment, the vaccine composition is a cocktail 5 formulation comprising a combination of at least 2, at least 3, at least 4 or 5 immunogenic polypeptides of amino acid sequence having at least 95% identity to a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9. In another embodiment, the vaccine composition is a cocktail formulation comprising a combination of the 10 immunogenic polypeptides of amino acid sequence having at least 95% identity to a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 59, SEQ ID 15 NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID NO: 67, SEQ ID NO: 69, SEQ ID NO: 71, SEQ ID NO: 73, SEQ ID NO: 75, SEQ ID NO: 77, SEQ ID NO: 79, and SEQ ID NO: 81. In another embodiment, the vaccine composition is a cocktail formulation comprising a combination of the immunogenic polypeptides of amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 20 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID NO: 67, SEQ ID NO: 69, SEQ ID NO: 71, SEQ ID NO: 73, SEQ ID NO: 75, SEQ ID NO: 77, SEQ ID NO: 25 79, and SEQ ID NO: 81.
[0076] In yet another embodiment, the vaccine composition is a cocktail formulation comprising a combination of at least 2, at least 3, at least 4 or 5 immunogenic polypeptides of amino acid sequence having at least 95% identity to a sequence selected from the group consisting of SEQ ID NO: 15, SEQ ID NO: 30 20, SEQ ID NO: 25, SEQ ID NO: 30, SEQ ID NO: 35, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID NO: 67, SEQ ID NO: 69, SEQ 22 ID NO: 71, SEQ ID NO: 73, SEQ ID NO: 75, SEQ ID NO: 77, SEQ ID NO: 79, and SEQ ID NO: 81. In yet another embodiment, the vaccine composition is a cocktail formulation comprising a combination immunogenic polypeptides of amino acid sequence having at least 95% identity to a sequence selected from the 5 group consisting of SEQ ID NO: 15, SEQ ID NO: 20, SEQ ID NO: 25, SEQ ID NO: 30, SEQ ID NO: 35, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID NO: 67, SEQ ID NO: 69, SEQ ID NO: 71, SEQ ID NO: 73, SEQ ID NO: 75, SEQ ID NO: 77, SEQ ID NO: 79, and SEQ ID NO: 81. In yet another embodiment, the vaccine composition is a cocktail formulation comprising 10 a combination immunogenic polypeptides of amino acid sequence selected from the group consisting of SEQ ID NO: 15, SEQ ID NO: 20, SEQ ID NO: 25, SEQ ID NO: 30, SEQ ID NO: 35, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID NO: 67, SEQ ID NO: 69, SEQ ID NO: 71, SEQ ID NO: 73, SEQ ID NO: 75, SEQ ID NO: 77, SEQ ID NO: 79, and SEQ ID NO: 81. 15 [0077] In an embodiment of the present disclosure, there is provided method for producing the vaccine composition as disclosed herein, said method comprising: (a) culturing the recombinant host cell as described herein, to express the immunogenic polypeptide as described herein; (b) subjecting the immunogenic polypeptide to purification; and (c) contacting the immunogenic polypeptide of 20 step (b) with a pharmaceutically acceptable carrier, to obtain the vaccine composition. The vector, according to embodiments herein, comprising the nucleotide encoding the immunogenic polypeptide may be introduced into the host cell by transfection, to obtain the recombinant host cell which may then be cultured to express the immunogenic polypeptide as described herein. Various transfection 25 methods are known for eg: lipofection, electroporation, etc which may be used to achieve the recombinant host cell as described herein. The expressed immunogenic polypeptide may then be purified by using protein purification methods generally known in field (for eg: Ni-NTA affinity chromatography) to obtain the purified immunogenic polypeptide. The immunogenic polypeptide may 30 then be mixed with a suitable pharmaceutically acceptable carrier to obtain the 23 vaccine composition. One or more immunogenic polypeptides may be mixed with the pharmaceutically acceptable carrier.
[0078] In an embodiment of the present disclosure, there is provided method for producing the vaccine composition as disclosed herein, said method 5 comprising: (a) culturing the recombinant host cell as described herein, under suitable conditions to express the immunogenic polypeptide, wherein the immunogenic polypeptide has an amino acid sequence of at least 95% sequence identity to amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 10 15, SEQ ID NO: 20, SEQ ID NO: 25, SEQ ID NO: 30, SEQ ID NO: 35, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID NO: 67, SEQ ID NO: 69, SEQ ID NO: 71, SEQ ID NO: 73, SEQ ID NO: 75, SEQ ID NO: 77, SEQ ID NO: 79, and SEQ ID NO: 81; (b) subjecting the immunogenic polypeptide to purification; and (c) contacting the immunogenic polypeptide of step (b) with a 15 pharmaceutically acceptable carrier, to obtain the vaccine composition.
[0079] In another embodiment, there is provided a method of eliciting an immune response against diverse Sarbecovirus in a subject, the method comprising administering the subject with an effective amount of the vaccine composition as disclosed herein. In another embodiment, the Sarbecovirus is selected from clade 20 1a, clade 1b, clade 2, or clade 3 virus. In another embodiment, the Sarbecoviruses is selected from the group consisting of SARS-CoV-1 (clade 1a), WIV-1 (clade 1a), SARS-CoV-2(clade 1b), RaTG13 (clade 1b), RmYN02 (clade 2), and BtKY72 (clade 3).
[0080] In another embodiment, the Sarbecovirus is selected from the group 25 consisting of SARS-CoV-1 (clade 1a), WIV-1 (clade 1a), SARS-CoV-2(clade 1b), RaTG13 (clade 1b), RmYN02 (clade 2), BtKY72 (clade 3), Pangolin_GD, RaTG13 (MN996532), Pangolin_GX-P2V (EPI_ISL_410542), SARS-CoV- 1_Urbani_HP03 (AY278741), SARS-CoV-1_BJ02_HP03M (AY278487), SARS- CoV-1_HGZ8L1-A_HP03E (AY394981), SARS-CoV-1_GD01_HP03L 30 (AY278489), SARS-CoV-1_GZ-C_HP03L (AY394979), SARS-CoV-1_Sino1- 11_HP03L (AY485277), SARS-CoV-1_Sin852_HP03L (AY559082), SARS- 24 CoV-1_SZ3_PC03 (AY304486), SARS-CoV-1_SZ13_PC03 (AY304487), SARS-CoV-1_SZ1_PC03 (AY304489), SARS-CoV-1_GD03T0013_HP04 (AY525636), SARS-CoV-1_GZ0402_HP04 (AY613947), SARS-CoV-1_PC4- 127_PC04 (AY613951), SARS-CoV-1_PC4-137_PC04 (AY627045), SARS- 5 CoV-1_PC4-13_PC04 (AY613948), WIV16 (KT444582), WIV1 (KF367457), Rs7327 (KY417151), LYRa11 (KF569996), Rs4231 (KY417146), RsSHC014 (KC881005), Rs4084 (KY417144), BM48-31 (NC014470), BtKY72 (KY352407), ZXC21 (MG772934), ZC45 (MG772933), JL2012 (KJ473811), Rf1 (DQ412042), HeB2013 (KJ473812), 273-2005 (DQ648856), Rf4092 10 (KY417145), YN2013 (KJ473816), RmYN02 (EPI_ISL_412977), As6526 (KY417142), Rs4237 (KY417147), Rs4081 (KY417143), Rp3 (DQ071615), 279- 2005 (DQ648857), Shaanxi2011 (JX993987), Yunnan2011 (JX993988), Rs4247 (KY417148), HKU3-13 (GQ153548), HKU3-1 (DQ022305), GX2013 (KJ473815), Longquan-140 (KF294457), HKU3-8 (GQ153543), HuB2013 15 (KJ473814), Hp-BCoV_Zhejiang_2013 (KF636752), HKU1 (KF686346), OC43 (KX344031), MERS-CoV (NC_019843), Bat-CoV-GCCDC1 (MT350598), Rousettus-CoV_HKU9 (MG762674), Rc-o319 (LC556375), RacCS203 (MW251308), RshSTT182 (EPI_ISL_852604), PDF-2370, PRD-0038, RsYN04 (EPI_ISL_1699444), BB9904 (KR559017), Khosta-1 (MZ190137), Khosta-2 20 (MZ190138), and RhGB01 (MW719567).
[0081] In an embodiment, the vaccine composition is administered by a mode selected from the group consisting of intranasal, subcutaneous, intravenous, intra-arterial, intra-peritoneal, intramuscular, intradermal, oral, dermal, and buccal. 25 [0082] In another embodiment, there is provided a kit comprising the immunogenic polypeptide as disclosed herein; or the vaccine composition as described herein, and an instruction leaflet.
[0083] Although the subject matter has been described with reference to specific embodiments, this description is not meant to be construed in a limiting 30 sense. Various modifications of the disclosed embodiments, as well as alternate embodiments of the subject matter, will become apparent to persons skilled in the 25 art upon reference to the description of the subject matter. It is therefore contemplated that such modifications can be made without departing from the spirit or scope of the present subject matter as defined. 5 EXAMPLES
[0084] The disclosure will now be illustrated with working examples, which is intended to illustrate the working of disclosure and not intended to take restrictively to imply any limitations on the scope of the present disclosure. Unless 10 defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this disclosure belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice of the disclosed methods and compositions, the exemplary methods, devices and materials are described herein. 15 It is to be understood that this disclosure is not limited to particular methods, and experimental conditions described, as such methods and conditions may vary.
[0085] Substitution mutations, in accordance with the embodiments herein are depicted in Table 1. 20 Table 1: depicts the substitution mutations, according to the present disclosure. SEQ ID NO. Virus name Mutations: positions in respect of RBD Mutations: positions in respect of the immunogenic polypeptide SEQ ID NO: 1 SARS CoV-1 Y352W, P513L Y34W, P195L SEQ ID NO: 3 WIV-1 Y365W, P526L Y34W, P195L 26 SEQ ID NO: 5 RaTG13 A348P, Y365W, P527L A17P, Y34W, P196L SEQ ID NO: 7 RmYN02 Y344W, P487L Y34W, P177L SEQ ID NO: 9 BtKY72 Y355W, P516L Y34W, P195L SEQ ID NO: 15 Mature stabilized SARS CoV-1 Y352W, P513L Y37W, P198L SEQ ID NO: 20 Mature stabilized WIV-1 Y365W, P526L Y37W, P198L SEQ ID NO: 25 Mature stabilized RaTG13 A348P, Y365W, P527L A20P, Y37W, P199L SEQ ID NO: 30 Mature stabilized RmYN02 Y344W, P487L Y37W, P180L SEQ ID NO: 35 Mature stabilized BtKY72 Y355W, P516L Y37W, P198L SEQ ID NO: 13 TPA- SARS CoV-1 Y352W, P513L Y60W, P221L SEQ ID NO: 18 TPA- WIV-1 Y365W, P526L Y60W, P221L SEQ ID NO: 23 TPA- RaTG13 A348P, Y365W, P527L A43P, Y60W, P222L 27 SEQ ID NO: 28 TPA- RmYN02 Y344W, P487L Y60W, P203L SEQ ID NO: 33 TPA- BtKY72 Y355W, P516L Y60W, P221L SEQ ID NO: 59 SARS CoV-1 RBD-S2 Y352W, P513L Y34W, P195L SEQ ID NO: 61 WIV-1 RBD-S2 Y365W, P526L Y34W, P195L SEQ ID NO: 63 RaTG13 RBD-S2 A348P, Y365W, P527L A17P, Y34W, P196L SEQ ID NO: 65 RmYN02 RBD-S2 Y344W, P487L Y34W, P177L SEQ ID NO: 67 BtKY72 RBD-S2 Y355W, P516L Y34W, P195L SEQ ID NO: 69 SARS CoV-2 XBB1.5 A348P, Y365W, P527L A17P, Y34W, P196L
[0086] Nucleic acid and amino acid sequences as disclosed in the present disclosure Table 2 depicts sequences used in the present disclosure SEQ ID NO. Sequence Type Description SEQ ID NO: 1 Protein Stabilized SARS CoV-1 SEQ ID NO: 2 Nucleotide Stabilized SARS CoV-1 SEQ ID NO: 3 Protein Stabilized WIV-1 SEQ ID NO: 4 Nucleotide Stabilized WIV-1 SEQ ID NO: 5 Protein Stabilized RaTG13 SEQ ID NO: 6 Nucleotide Stabilized RaTG13 SEQ ID NO: 7 Protein Stabilized RmYN02 28 SEQ ID NO: 8 Nucleotide Stabilized RmYN02 SEQ ID NO: 9 Protein Stabilized BtKY72 SEQ ID NO: 10 Nucleotide Stabilized BtKY72 SEQ ID NO: 11 Protein WT SARS CoV-1 (Accession Id : 5XLR) SEQ ID NO: 12 Nucleotide WT SARS CoV-1 (Accession Id: MK062184.1) SEQ ID NO: 13 Protein tPA signal-linker-Stabilized SARS CoV- 1 RBD sequence-linker-cCMP IzM V2 oligomer motif-linker-HRV3C site- 10xHis tag-linker-stop codon SEQ ID NO: 14 Nucleotide tPA signal-linker-Stabilized SARS CoV- 1 RBD sequence-linker-cCMP IzM V2 oligomer motif-linker-HRV3C site- 10xHis tag-linker-stop codon SEQ ID NO: 15 Protein Mature stabilized SARS CoV-1 sequence SEQ ID NO: 16 Protein WT WIV-1 (Accession Id: 7TTY) SEQ ID NO: 17 Nucleotide WT WIV-1 (Accession Id: KC881007.1) SEQ ID NO: 18 Protein tPA signal-linker-Stabilized WIV-1 RBD sequence-linker-cCMP IzM V2 oligomer motif-linker-HRV3C site-10xHis tag-linker-stop codon SEQ ID NO: 19 Nucleotide tPA signal-linker-Stabilized WIV-1 RBD sequence-linker-cCMP IzM V2 oligomer motif-linker-HRV3C site-10xHis tag-linker-stop codon SEQ ID NO: 20 Protein Mature stabilized WIV-1 sequence SEQ ID NO: 21 Protein WT RaTG13 (Accession Id: 7DRV) SEQ ID NO: 22 Nucleotide WT RaTG13 (Accession Id: MN996532.2) 29 SEQ ID NO: 23 Protein tPA signal-linker-Stabilized RaTG13 RBD sequence-linker-cCMP IzM V2 oligomer motif-linker-HRV3C site- 10xHis tag-linker-stop codon SEQ ID NO: 24 Nucleotide tPA signal-linker-Stabilized RaTG13 RBD sequence-linker-cCMP IzM V2 oligomer motif-linker-HRV3C site- 10xHis tag-linker-stop codon SEQ ID NO: 25 Protein Mature stabilized RaTG13 sequence SEQ ID NO: 26 Protein WT RmYN02 SEQ ID NO: 27 Nucleotide WT RmYN02 (Accession Id: EPI_ISL_412977) SEQ ID NO: 28 Protein tPA signal-linker-Stabilized RmYN02 RBD sequence-linker-cCMP IzM V2 oligomer motif-linker-HRV3C site- 10xHis tag-linker-stop codon SEQ ID NO: 29 Nucleotide tPA signal-linker-Stabilized RmYN02 RBD sequence-linker-cCMP IzM V2 oligomer motif-linker-HRV3C site- 10xHis tag-linker-stop codon SEQ ID NO: 30 Protein Mature stabilized RmYN02 sequence SEQ ID NO: 31 Protein WT BtKY72 (Accession Id: 8K4U) SEQ ID NO: 32 Nucleotide WT BtKY72 (Accession Id: KY352407.1) SEQ ID NO: 33 Protein tPA signal-linker-Stabilized BtKY72 RBD sequence-linker-cCMP IzM V2 oligomer motif-linker-HRV3C site- 10xHis tag-linker-stop codon 30 SEQ ID NO: 34 Nucleotide tPA signal-linker-Stabilized BtKY72 RBD sequence-linker-cCMP IzM V2 oligomer motif-linker-HRV3C site- 10xHis tag-linker-stop codon SEQ ID NO: 35 Protein Mature stabilized BtKY72 sequence SEQ ID NO: 36 Protein tPA signal SEQ ID NO: 37 Nucleotide tPA signal (Nucleotide sequence for SEQ ID 31) SEQ ID NO: 38 Protein cCMP IzM V2 oligomer motif SEQ ID NO: 39 Nucleotide cCMP IzM V2 oligomer motif (Nucleotide sequence for SEQ ID 33) SEQ ID NO: 40 Protein HRV3C site SEQ ID NO: 41 Nucleotide HRV3C site (Nucleotide sequence for SEQ ID 35) SEQ ID NO: 42 Protein His tag SEQ ID NO: 43 Nucleotide His tag (Nucleotide sequence for SEQ ID 37) SEQ ID NO: 44 Protein linker 1 SEQ ID NO: 45 Nucleotide linker 1 (Nucleotide sequence for SEQ ID 33) SEQ ID NO: 46 Protein linker 2 SEQ ID NO: 47 Nucleotide linker 2 (Nucleotide sequence for SEQ ID 35) SEQ ID NO: 48 Protein linker 3 SEQ ID NO: 49 Nucleotide linker 3 (Nucleotide sequence for SEQ ID 37) SEQ ID NO: 50 Protein Stop Codon SEQ ID NO: 51 Nucleotide Stop codon (Nucleotide sequence for SEQ ID 50) 31 SEQ ID NO: 52 Protein linker 4 SEQ ID NO: 53 Nucleotide linker 4 SEQ ID NO: 54 Protein Stabilized SARS CoV-1 RBD sequence-linker-cCMP IzM V2 oligomer motif-linker-HRV3C site-10xHis tag-linker-stop codon (without TPA) SEQ ID NO: 55 Protein tPA signal-linker-Stabilized WIV-1 RBD sequence-linker-cCMP IzM V2 oligomer motif-linker-HRV3C site-10xHis tag-linker-stop codon (without TPA) SEQ ID NO: 56 Protein Stabilized RaTG13 RBD sequence-linker-cCMP IzM V2 oligomer motif-linker-HRV3C site-10xHis tag-linker-stop codon SEQ ID NO: 57 Protein Stabilized RmYN02 RBD sequence-linker-cCMP IzM V2 oligomer motif-linker-HRV3C site-10xHis tag-linker-stop codon SEQ ID NO: 58 Protein Stabilized BtKY72 RBD sequence-linker-cCMP IzM V2 oligomer motif-linker-HRV3C site-10xHis tag-linker-stop codon SEQ ID NO: 59 Protein Stabilized SARS CoV-1 RBD-S2 SEQ ID NO: 60 nucleotide Stabilized SARS CoV-1 RBD-S2 SEQ ID NO: 61 Protein Stabilized WIV-1 RBD-S2 SEQ ID NO: 62 nucleotide Stabilized WIV-1 RBD-S2 SEQ ID NO: 63 Protein Stabilized RaTG13 RBD-S2 SEQ ID NO: 64 nucleotide Stabilized RaTG13 RBD-S2 SEQ ID NO: 65 Protein Stabilized RmYN02 RBD-S2 SEQ ID NO: 66 nucleotide Stabilized RmYN02 RBD-S2 SEQ ID NO: 67 Protein Stabilized BtKY72 RBD-S2 32 SEQ ID NO: 68 nucleotide Stabilized BtKY72 RBD-S2 SEQ ID NO: 69 Protein Stabilized SARS CoV-2 XBB1.5 RBD- S2 SEQ ID NO: 70 nucleotide Stabilized SARS CoV-2 XBB1.5 RBD- S2 SEQ ID NO: 71 Protein tPA signal-linker- Stabilized SARS CoV- 1 RBD-linker-S2 sequence-linker- HRV3C site-His tag-stop codon SEQ ID NO: 72 nucleotide tPA signal-linker-Stabilized SARS CoV- 1 RBD-linker-S2 sequence-linker- HRV3C site-His tag-stop codon SEQ ID NO: 73 Protein tPA signal-linker- Stabilized WIV-1 RBD-linker-S2 sequence-linker-HRV3C site-His tag-stop codon SEQ ID NO: 74 nucleotide tPA signal-linker- Stabilized WIV-1 RBD-linker-S2 sequence-linker-HRV3C site-His tag-stop codon SEQ ID NO: 75 Protein tPA signal-linker-Stabilized RaTG13 RBD-S2-linker-S2 sequence-linker- HRV3C site-His tag-stop codon SEQ ID NO: 76 nucleotide tPA signal-linker- Stabilized RaTG13 RBD-S2-linker-S2 sequence-linker- HRV3C site-His tag-stop codon SEQ ID NO: 77 Protein tPA signal-linker- Stabilized RmYN02 RBD-linker-S2 sequence-linker-HRV3C site-His tag-stop codon SEQ ID NO: 78 nucleotide tPA signal-linker-Stabilized RmYN02 RBD-linker-S2 sequence-linker-HRV3C site-His tag-stop codon SEQ ID NO: 79 Protein tPA signal-linker- Stabilized BtKY72 RBD-linker-S2 sequence-linker-HRV3C site-His tag-stop codon SEQ ID NO: 80 nucleotide tPA signal-linker-Stabilized BtKY72 RBD-linker-S2 sequence-linker-HRV3C site-His tag-stop codon SEQ ID NO: 81 Protein tPA signal-linker- Stabilized SARS CoV- 2 XBB1.5 RBD-linker-S2 sequence-linker-HRV3C site-His tag-stop codon SEQ ID NO: 82 nucleotide tPA signal-linker- Stabilized SARS CoV- 2 XBB1.5 RBD-linker-S2 sequence-linker-HRV3C site-His tag-stop codon SEQ ID NO: 83 Protein S2 subunit of SARS-CoV-2 33 SEQ ID NO: 84 nucleotide S2 subunit of SARS-CoV-2 SEQ ID NO: 85 Protein SARS CoV-2 XBB1.5 RBD SEQ ID NO: 86 nucleotide SARS CoV-2 XBB1.5 RBD Example 1: Stabilization of diverse Sarbecoviruses RBDs
[0087] The percentage amino acid identity of the specific RBDs was compared with SARS-CoV2 RBD and with other members of the respective 5 clades. Considering the conservation of RBD sequence within the clade, SARS- CoV-1 and WIV-1 (clade 1a); SARS-CoV-2 B.1, SARS-CoV-2 XBB1.5 and RaTG13 (clade 1b); RmYN02 (clade 2) and BtKY72 (clade 3) were selected as the representatives for their respective clades. The sequence and structural conservation of the target residues was analysed. While residues 365 and 527 were 10 fully conserved in all the selected Sarbecoviruses, it was interesting to note that one of the SARS CoV-2 stabilizing mutations A348P was naturally present in clade 1a, 2 and 3 viruses. A348P, Y365W and P527L mutations were introduced in the selected Sarbecoviruses in order to study the transferability of these mutations in diverse sequence backgrounds. 15 Methods
[0088] The polypeptide fragments were prepared using the immunogenic polypeptide sequences depicted in SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, and SEQ ID NO: 9, and the oligomerization domain (SEQ IN NO: 20 38). The polypeptide fragments were expressed and tested for stability and immunogenicity. The polypeptide fragments had the sequences as set forth in SEQ ID NO: 13 without TPA signal, SEQ ID NO: 18 without TPA signal, SEQ ID NO: 23 without TPA signal, SEQ ID NO: 28 without TPA signal, and SEQ ID NO: 33 without TPA signal. The sequences as set forth in SEQ ID NO: 13 without TPA 25 signal, SEQ ID NO: 18 without TPA signal, SEQ ID NO: 23 without TPA signal, SEQ ID NO: 28 without TPA signal, and SEQ ID NO: 33 without TPA signal are 34 as depicted in SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, and SEQ ID NO: 58, respectively.
[0089] Each of the polypeptides having sequences depicted in SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, and SEQ ID NO: 9, were 5 independently fused with a fragment of S2 subunit (SEQ ID NO: 83) at the C-terminal end using a linker “AS” to obtain stabilized SARS CoV-1 RBD-S2 (SEQ ID NO: 59), Stabilized WIV-1 RBD-S2 (SEQ ID NO: 61); Stabilized RaTG13 RBD-S2 (SEQ ID NO: 63); Stabilized RmYN02 RBD-S2 (SEQ ID NO: 65); and Stabilized BtKY72 RBD-S2 (SEQ ID NO: 67), respectively. The polypeptide 10 having a sequence depicted in SEQ ID NO: 85 was fused with a fragment of S2 subunit (SEQ ID NO: 83) at the C-terminal end using a linker “AS” to obtain stabilized SARS CoV-2 XBB1.5 RBD-S2 (SEQ ID NO: 69).
[0090] The cocktail formulations were prepared using the polypeptide fragments as depicted in SEQ ID NO: 13 without TPA signal, SEQ ID NO: 18 15 without TPA signal, SEQ ID NO: 23 without TPA signal, SEQ ID NO: 28 without TPA signal, and SEQ ID NO: 33 without TPA signal, combined with SWE adjuvant, at 1:1 v/v polypeptide fragments: adjuvant ratio, and neutralization titers. The 1:1 v/v polypeptide fragments: adjuvant ratio. The cocktail formulations may also be prepared using the polypeptide fragments selected from SEQ ID NO: 1, 20 SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 15, SEQ ID NO: 20, SEQ ID NO: 25, SEQ ID NO: 30, SEQ ID NO: 35, SEQ ID NO: 71, SEQ ID NO: 73, SEQ ID NO: 75, SEQ ID NO: 77, SEQ ID NO: 79, and SEQ ID NO: 81. 25 Protein Expression and Purification
[0091] The genes encoding Sarbecoviruses RBD proteins and monoclonal antibodies (mAbs) were synthesized at GenScript (USA) and TWIST Biosciences (USA). All the RBD derivatives [ i.e. SEQ ID NO: 13 without TPA signal, SEQ ID NO: 18 without TPA signal, SEQ ID NO: 23 without TPA signal, SEQ ID NO: 30 28 without TPA signal, and SEQ ID NO: 33 without TPA signal] were purified from transiently transfected Expi293F cells following the manufacturer’s 35 guidelines (Gibco, Thermo Fisher, Waltham, MA, USA). Briefly, Expi293F cells were diluted to a density of 3 × 106 cells/mL. For transfection, the desired plasmid (pCDNA5FRTTO mammalian expression vector) was complexed with ExpiFectamine293 according to the manufacturer’s protocol and transiently 5 transfected into Expi293F cells. Enhancer 1 and Enhancer 2 were added 16 hours post transfection. The culture supernatant was collected after 5 days, and protein was purified through Ni-NTA affinity chromatography using Ni Sepharose 6 fast-flow resin (GE Healthcare, Chicago, IL, USA) for RBD derivatives. The supernatant was added to a pre-equilibrated Ni-NTA column. Following a 2- 10 column wash with 1× PBS (pH 7.4) supplemented with 20 mM imidazole, the protein was eluted in 1X PBS with 300mM imidazole (pH 7.4). Pooled eluted fractions were dialyzed thrice against 1× PBS (pH 7.4). For expression and purification of mAbs, Expi293F cells were co-transfected by Heavy and Light chain plasmids in 1:1 ratio by using polyethylenimine, and supernatants were 15 harvested after 5 days post-transfection. The antibodies were purified from supernatants by using Protein A/G beads, dialyzed and stored in phosphate buffered saline (PBS) for further use. Purified protein samples were analyzed on 12% SDS-PAGE gel and quantified using NanoDrop spectrophotometer (Figure 1, Table 3). Table 3 depicts summary of purified yields of Sarbecoviruses RBD 20 derivatives. Similarly, the immunogenic polypeptide selected from SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 15, SEQ ID NO: 20, SEQ ID NO: 25, SEQ ID NO: 30, SEQ ID NO: 35, SEQ ID NO: 71, SEQ ID NO: 73, SEQ ID NO: 75, SEQ ID NO: 77, SEQ ID NO: 79, and SEQ ID NO: 81 may also be expressed and purified. 25 Table 3: RBD Clade Yield(mg/L) WT CoV -1 Trimer 1a 72 Stabilized CoV-1 Trimer 1a 84 WT WIV -1 Trimer 1a 54 36 Stabilized WIV-1 Trimer 1a 144 WT RaTG13 Trimer -RBD 1b 5.6 Stabilized RaTG13 Trimer- RBD 1b 85 WT RmYN02 Trimer 2 8.09 Stabilized RmYN02 Trimer 2 189 WT BtKY72 Trimer -RBD 3 12.4 Stabilized BtKY72 Trimer -RBD 3 48.6 Thermal Unfolding experiments
[0092] Thermal melting studies of the RBD derivatives [ i.e. SEQ ID NO: 13 without TPA signal, SEQ ID NO: 18 without TPA signal, SEQ ID NO: 23 without TPA signal, SEQ ID NO: 28 without TPA signal, and SEQ ID NO: 33 5 without TPA signal] were performed using nanoDSF (Prometheus NT.48), as described in Chattopadhyay, G. et.al, 2019, at a temperature range of 20 °C to 95 °C. Experimental measurements were conducted at 100% LED intensity with an initial discovery scan, and the scan counts (350 nm) ranged between 2000 and 3000. For lyophilized protein, reconstitution was done using 1X PBS buffer before 10 the DSF experiment. The results have been summarized in Figure 2. SPR binding studies
[0093] Kinetics titrations were performed using a CM5 sensor chip (Cytiva) at 25°C. The activation of the carboxymethylated-dextran gold surface was achieved by injecting EDC/s-NHS (2/4 mM) solution in autoclaved water pH 7.0 15 injected at 5 µL/min for 400 seconds. Following the activation step, a 10 µg/mL solution of Protein-G in sodium acetate (NaOAc) pH 5.0 was injected over the activated surface at 5 µL/min. After covalent modification of the sensor surface, a quenching solution of ethanolamine pH 8.5 (Cytiva) was injected over the surface for 600 seconds to cap any residual active NHS esters. PBS (1X) pH 7.4 was used 20 for the running buffer during titration. During the kinetics assay, one flow cell channel with only Protein G served as a reference channel to monitor and subtract 37 binding responses due to non-specific interactions. 200-300 RU of monoclonal antibodies at 1 µg/mL were captured onto the chip surface for each cycle at 5 µL/min for 60 seconds, followed by injection of RBD derivatives for 200 seconds. Then a dissociation step was performed using an injection of running buffer for 5 200 seconds. Following the dissociation step, regeneration of the Protein G surface was performed using 1 injection of 0.1M glycine-HCl, pH 2.0 at 30 µL/min for 40 seconds. The flow rate for association and dissociation was 30 µL/min. The kinetics traces were reference subtracted using the responses of the reference channel in each cycle and blank subtracted using a zero-concentration cycle. Then 10 the kinetics constants ka, kd and KD values were determined using Biacore T200 evaluation software. Mice Immunizations
[0094] Female C57BL/6 mice (6–8 weeks old, n = 5/group) were immunized intramuscularly with RBD derivatives [ i.e. SEQ ID NO: 13 without TPA signal, 15 SEQ ID NO: 18 without TPA signal, SEQ ID NO: 23 without TPA signal, SEQ ID NO: 28 without TPA signal, and SEQ ID NO: 33 without TPA signal], (5µg/animal in 100 µL of 1× PBS, pH 7.4) adjuvanted with SWE (1:1 v/v antigen: adjuvant ratio) (Sepivac SWE Batch No. 200915012131, Cat. No. 80748J, SEPPIC SA) on days 0 (prime), and 21 (boost). RBD cocktail group was 20 immunized with 5µg/antigen having RBD derivatives from different clades as mentioned. Sera were isolated from blood drawn on days prior to prime (day -1), post-prime (day 14), and post-boost (day 35) through retro-orbital puncture.
[0095] For the assessment of RBD cocktail efficacy in pre-immunized mice, female BALB/c mice (6–8 weeks old, n = 5/group) were first immunized with 25 stabilized monomeric SARS CoV-2 RBD (1µg/animal in 100 µL of 1× PBS, pH 7.4) adjuvanted with SWE (1:1 v/v antigen: adjuvant ratio) (Sepivac SWE Batch No. 200915012131, Cat. No. 80748J, SEPPIC SA) on days 0 (prime), and then boosted with RBD cocktail formulation (having SEQ ID NO: 13 without TPA signal, SEQ ID NO: 18 without TPA signal, SEQ ID NO: 23 without TPA signal, 30 SEQ ID NO: 28 without TPA signal, and SEQ ID NO: 33 without TPA signal) (5µg/antigen, total 30µg) on day 30 and day 51. Sera obtained before prime and 38 post boost immunizations was used to conduct ELISA and pseudoviral neutralization assays. These studies were performed at Central Animal Facility, Indian Institute of Science. The Institutional Animal Ethics committee approved all animal studies (IAEC no. CAF/ETHICS/002/2023). Similarly, studies may also 5 be performed using cocktail formulations having SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 15, SEQ ID NO: 20, SEQ ID NO: 25, SEQ ID NO: 30, SEQ ID NO: 35, SEQ ID NO: 71, SEQ ID NO: 73, SEQ ID NO: 75, SEQ ID NO: 77, SEQ ID NO: 79, and/or SEQ ID NO: 81. Enzyme-linked immunosorbent assay (ELISA) 10 [0096] ELISA was used to quantify the Sarbecoviruses RBD-specific IgG titers in serum as described in Ahmed, S. et al. 2021. Briefly, ELISA plates were coated with 4 µg/mL His tagged RBD derivatives at 25 °C, 1h. The coated plates were blocked using blocking buffer (PBS containing 3% skimmed milk) for 1 hour at 25 °C. The sera (maximum concentration, 1:80-1:1280) from mice, were serially 15 diluted 1:4 in PBST (PBS containing 3% skimmed milk and 0.05% Tween-20) for 8 dilutions, followed by incubation with the coated ELISA plates for 60 min at 25 °C. After washing with PBST three times, HRP-conjugated secondary antibody was added to the plates and incubated for 60 min at 25 °C. After incubation with the secondary antibody, the plates were washed with PBST three times, followed 20 by adding 3,3’,5,5’-tetramethylbenzidine (TMB) to visualize the reaction. Finally, 6N HCl was used to stop the reaction. The chromogenic signal was measured at 405 nm using an ELISA plate reader (Maxome Labsciences Cat # P3-5x10NO). The serum dilution with a signal observed two-fold above the negative control (empty blocked wells) was considered the endpoint titer for ELISA. 25 Sarbecoviruses Pseudovirus Preparation and Neutralization Assay
[0097] HIV-1-based pseudotyped viruses were employed in pseudoviral neutralization assays, following a method previously described [Malladi SK, et al. Immunogenicity and Protective Efficacy of a Highly Thermotolerant, Trimeric 30 SARS-CoV-2 Receptor Binding Domain Derivative. ACS Infect Dis. 2021 Aug 13;7(8):2546-2564. doi: 10.1021/acsinfecdis.1c00276. Epub 2021 Jul 14. PMID: 39 34260218; PMCID: PMC8996237.]. Briefly, adherent HEK293T cells were transiently transfected with plasmid DNA pHIV-1 NL4-3?env-Luc and Sarbecoviruses spike plasmids, using the ProFection mammalian transfection kit (Cat# E1200, Promega Inc., Singapore) for pseudovirus production. The genes 5 encoding Spike proteins from SARS CoV-2 VOCs were synthesized at GenScript (USA) while spike plasmids encoding Sarbecoviruses spikes were kindly gifted by Dr. Pamela J. Bjorkman (Caltech, USA). The culture supernatant was harvested 48 h post-transfection, filtered through a 0.22 µm filter, and stored at -80 °C. Adherent HEK293 cells expressing hACE-2 and TMPRSS2 receptors (BEI 10 resources, NIH, Catalog No. NR-55293) were cultured in a growth medium consisting of DMEM with 5% Fetal Bovine Serum (Thermo Fisher) and penicillin–streptomycin (100 U/mL). Mice serum samples were heat-inactivated and then serially diluted in the growth medium, starting from 1:20 dilutions. In the next step, the pseudotyped virus was incubated with the serially diluted sera in a 15 total volume of 100 µL for 1 h at 37 °C. The adherent cells were then trypsinized, and 1 × 104 cells/well were added to achieve a final volume of 200 µL/well. The plates were further incubated for 48 h in a humidified CO2 incubator at 37 °C. After incubation, neutralization was measured as an indicator of luciferase activity in the cells (relative luminescence units) using Nano-Glo luciferase substrate (Cat 20 # N1110, Promega). Luminescence was measured using a Cytation-5 multimode reader (Bio-Tech Inc., Oklahoma City, OK, USA). The luciferase activity, measured as relative luminescence units (RLU), in the absence of sera was considered as 100% infection. The serum dilution resulting in half-maximal neutralization of the pseudovirus (ID50) relative to the no-serum control was 25 determined from neutralization curves. Biolayer Interferometry experiment
[0098] The long-term stability of lyophilized RBD cocktail the RBD cocktail (having SEQ ID NO: 13 without TPA signal, SEQ ID NO: 18 without TPA signal, SEQ ID NO: 23 without TPA signal, SEQ ID NO: 28 without TPA signal, and 30 SEQ ID NO: 33 without TPA signal) was assessed through DSF and BLI binding studies. BLI measurements were made using ForteBio biosensors (Fortebio - 40 Sartorius). All data collection were performed at 25°C using settings of Standard Kinetics Acquisition rate at a sample plate shake speed of 1000 rpm. mAbs were loaded onto Protein G sensors, subsequently they were dipped into 1x PBS buffer for 60 seconds to obtain baseline and then dipped into wells containing RBD 5 derivatives at different concentrations in 1X PBS to monitor antibody association. The dissociation step was monitored for 200 seconds by dipping Ab-bound sensors into buffer. Antigen specific binding responses were obtained by subtracting responses of blank sensors tested in parallel with 1X kinetics buffer. The specific binding responses were fitted using ForteBio Data Analysis 12.0 software tool. 10 Statistical Analysis
[0099] The p values for ELISA binding and neutralization titres were analyzed with a two-tailed Mann–Whitney test using the GraphPad Prism software 9.0.0 (* indicates p < 0.05, ** indicates p < 0.01, **** indicates p < 0.0001). VOC pseudoviral neutralization titre data were analyzed with non-parametric Kruskal– 15 Wallis with Dunn’s multiple-comparison tests using the GraphPad Prism software 9.0.0 (* indicates p < 0.05, ** indicates p < 0.01, **** indicates p < 0.0001). Example 2: Thermal stabilization and yield enhancement by transfer of stabilizing mutations to diverse Sarbecoviruses RBDs without affecting 20 conformational integrity
[00100] SARS-CoV-1 shares 74% amino acid identity with SARS CoV-2 RBD and is closely related to another clade 1a member, WIV-1 (96% identical) (Table 4). Table 4 depicts percentage amino acid identity of the polypeptide of receptor binding domain (RBD) of Sarbecoviruses from different clades with that 25 of SARS CoV-2. 41 Table 4: Virus Clade Host Species % aa identity with SARS- CoV2(RBD) SARS CoV-2 ½ or 1b Homo Sapiens 100 RaTG13 ½ or 1b Rhinolophus affinis 90 SARS Cov-1 1 or 1a Homo Sapiens 74 WIV-1 1 or 1a Rhinolophus sinicus 77 RsSHC014 1 or 1a Rhinolophus sinicus 77 RfI 2 Rhinolophus ferrumequium 70 RmYN02 2 Rhinolophus malayanus 68 BtKY72 3 Rhinolophus sp. 74
[00101] WIV-1 is found in horseshoe bats (Rhinolophus sinicus) in China; its usage of ACE2 as the receptor highlights the potential for zoonotic transmission 5 to humans. RaTG13 exhibited high genetic similarity with SARS-CoV-2, it was also identified in horseshoe bats (Rhinolophus affinis) in Yunnan Province, China. Similar to SARS-CoV-2, RaTG13 is capable of utilizing the angiotensin-converting enzyme 2 (ACE2) receptor for cell entry. RmYN02 is a recently discovered clade-2 virus which contains two deletions in the RBD that prevents it 10 from using ACE2. Another SARS-related CoV that was included by the inventors, is BtKY72 (clade-3) which was identified in Kenyan Rhinolophus bats and shows human ACE2-dependent entry. As oligomerization of antigen results in enhanced immunogenicity, the inventors expressed the wild type (WT) and stabilized (St) derivatives of these Sarbecoviruses RBDs in Expi-293F cells (Recombinant host 15 cell) as oligomers through genetic fusion of a disulfide linked oligomerization motif at the respective C termini. For comparison, monomeric WT and Stabilized derivatives of SARS-CoV-1 RBD were also expressed and purified. 42
[00102] Purification of these mammalian cell expressed proteins was performed via Ni-affinity chromatography. A significant enhancement in the yield (~4-23-fold increase) of the RBD derivatives (Immunogenic polypeptides) was observed upon introduction of the stabilizing mutations. The effect of these 5 mutations on protein thermal stability was probed by assessing the apparent thermal melting temperature (Tm) of the WT and stabilized derivatives through nano-DSF. A notable increase (~7°C) in the Tm of the stabilized derivatives relative to the wild type RBDs was observed. To verify proper folding of these RBD derivatives, the binding was examined with a selected panel of broadly 10 neutralizing antibodies (bNAbs) that bind to different epitopes on RBD by using SPR. Due to the lack of conservation in class 1 and class 2 RBD epitopes, it is improbable for antibodies within these categories to exhibit significant cross-reactivity towards Sarbecoviruses RBDs. However, class 3 and class 4 RBD-binding antibodies present more promising opportunities for neutralization across 15 various clades, thereby offering potential protection against emerging Sarbecoviruses. The epitope of bnAb10-40 is similar to the previously defined ‘class 4’ antibody epitope, it makes polar contacts and hydrophobic interactions with RBD residues (377-385). ADG-20 binds to a class ¼ epitope that overlaps with the ACE2 binding site. This bnAb binds to RBDs from clade 1a, 1b and 3; 20 however, there was no binding observed for the clade 2 RmYN02 RBD which also does not bind ACE2. S2X259 targets the conserved antigenic site II within the RBD. It interacts with amino acid residues 369-386, 404-411 and 499-50836. All the RBD derivatives (i.e. SEQ ID NO: 13 without TPA signal, SEQ ID NO: 18 without TPA signal, SEQ ID NO: 23 without TPA signal, SEQ ID NO: 28 without 25 TPA signal, and SEQ ID NO: 33 without TPA signal) except the stabilized RmYN02 oligomer bound to this bnAb, this could be due to loss of conservation of residue D405 and G504 in RmYN02 RBD (i.e. SEQ ID NO: 28 without TPA signal) which are crucial for interaction with S2X259. All the stabilized RBD derivatives also bound to class 4 bnAb CR3022. 30 [00103] To probe the thermal tolerance conferred by these mutations, the WT and St RBD derivatives were incubated at different temperatures ranging from 4°C 43 to 70°C for 2 hours. The proteins were cooled to room temperature and subjected to DSF. The thermal melt curves clearly demonstrated the extended thermal tolerance of the stabilized derivatives relative to the corresponding WT RBDs (Figure 3). Collectively, these results illustrate that mutations are stabilizing in all 5 the Sarbecoviruses included in this study; they not only result in enhanced thermal stability and thermal tolerance but also increase the yield of the purified proteins significantly. Binding experiments confirm that the stabilized RBD derivatives are properly folded. 10 Example 3: Eliciting neutralizing antibody responses in mice against diverse Sarbecoviruses using stabilized RBD derivatives and a corresponding cocktail formulation.
[00104] To assess the immunogenicity of the stabilized Sarbecoviruses RBD derivatives, female C57BL/6 mice (n=5/group) were immunized intramuscularly 15 with individual RBD derivatives (5mg of stabilized RBDs from SARS-CoV-1 and WIV-1 (clade 1a); SARS CoV-2 and RaTG13 (clade 1b); RmYN02 (clade 2) and BtKY72 (clade 3), individually, (i.e. SEQ ID NO: 13 without TPA signal, SEQ ID NO: 18 without TPA signal, SEQ ID NO: 23 without TPA signal, SEQ ID NO: 28 without TPA signal, and SEQ ID NO: 33 without TPA signal) adjuvanted with 20 SWE (pharmaceutically acceptable carrier) in a prime-boost regimen.
[00105] The immunogenicity of a Sarbecoviruses RBD cocktail (Vaccine composition) having 5mg of each of the stabilized RBDs from SARS-CoV-1 and WIV-1 (clade 1a); SARS CoV-2 and RaTG13 (clade 1b); RmYN02 (clade 2) and BtKY72 (clade 3) (i.e. SEQ ID NO: 13 without TPA signal, SEQ ID NO: 18 25 without TPA signal, SEQ ID NO: 23 without TPA signal, SEQ ID NO: 28 without TPA signal, and SEQ ID NO: 33 without TPA signal) formulated with SWE as the adjuvant was evaluated.
[00106] Post boost immunization, ELISA against respective RBDs was done to determine the serum IgG titres (Figure 4). High antibody titres were observed 30 upon immunization with individual RBD derivatives, as well as with the RBD cocktail. In the context of SARS CoV-1 immunogens, enhancement in the 44 immunogenicity of the monomeric RBD derivative upon stabilization; however, in trimeric format this difference was insignificant. The stabilized monomeric SARS CoV-1 RBD derivative elicited higher neutralizing antibody (NAb) titres against homologous (SARS-CoV-1, WIV-1) and heterologous (LYRa3, SHC014) 5 clade1a pseudoviruses related to WT RBD. In contrast, the WT and mutant trimeric derivatives demonstrated comparable neutralizing titres. The RBD cocktail elicited good neutralization against homologous SARS CoV-1, WIV-1 (clade 1a); SARS CoV-2 B.1 (clade 1b) and BtKY72 (clade 3) and heterologous pseudoviruses (clade1a: LYRa3, SHC014; clade3: Khosta-2) (Figure 5). 10 Importantly with a single RBD immunization, clade matched pseudoviruses were effectively neutralized but no cross neutralization of mismatched pseudoviruses was observed. This emphasizes the need for incorporating RBDs from all the clades to achieve a broadly neutralizing pan-sarbecoviruses response. Unfortunately, the neutralization titres against clade 2 viruses could not be 15 assessed as they do not bind ACE2 and thus a suitable neutralization assay was not available. Overall, the RBD cocktail formulation elicited good neutralizing titres against all the RBDs incorporated in the formulation confirming the immunogenicity of the RBD derivatives in individual as well as cocktail format. It also elicited neutralization against all the heterologous pseudoviruses tested, 20 indicating elicitation of a broad neutralization response in the immunized animals. Example 4: Induction of an immunogenic response in pre-immunized mice using stabilized RBD cocktail (vaccine composition).
[00107] The inventors aimed to deduce whether the RBD cocktail formulation 25 (vaccine composition) could induce comparable responses in pre-immunized animals and naïve mice. Female BALB/c mice (n=5/group) were immunized with SARS CoV-2 B.1 RBD (5mg) followed by two boost immunizations with the stabilized RBD cocktail formulation (30mg). Serum ELISA demonstrated the presence of IgG titres against Sarbecoviruses RBDs after boost 1, boost 2 did not 30 result in further increase in antibody titres. However, with sera from the first boost, only weak and sporadic neutralization of homologous as well as heterologous 45 pseudovirus was observed. Consistent, broad neutralization was observed only after the second boost of the RBD cocktail. Consistent with the previous results in naïve mice; the pan-Sarbecoviruses formulation was able to elicit broad neutralizing responses against Sarbecoviruses after two immunizations in pre- 5 immunized mice, confirming its relevance in the current scenario. Example 5: Analysing antigenicity retention of the lyophilized RBD cocktail (vaccine composition).
[00108] To assess the long-term stability of the RBD cocktail formulation 10 (having SEQ ID NO: 13 without TPA signal, SEQ ID NO: 18 without TPA signal, SEQ ID NO: 23 without TPA signal, SEQ ID NO: 28 without TPA signal, and SEQ ID NO: 33 without TPA signal), it was subjected to lyophilization and incubated at either 4 or 37°C for a duration of one month. The stability of the formulations were confirmed through DSF and BLI experiments. As depicted in 15 Figure 7, the lyophilized formulation stored at both 4 and 37°C exhibited similar melting profiles up until day 15. However, a slight reduction in stability was observed on day 30. Additionally, the conformational integrity of the RBD cocktail was assessed by examining binding with the previously described bNAbs (CR3022, 10-40, ADG-20, S2X259). Consistent with the DSF analysis, the 20 lyophilized formulation demonstrated appropriate binding curves with all the antibodies until day 15, with a slight decrease in binding signal observed on day 30. These findings illustrate the long-term stability of the cocktail formulation when in a lyophilized state, an important factor to consider when evaluating potential vaccine candidate formulation. 25 Results and Conclusion
[00109] The results demonstrate that the stabilizing mutations are effective for clade members: SARS CoV-1, WIV-1 (clade 1a); SARS CoV-2 B.1 (clade 1b) and BtKY72 (clade 3) and heterologous pseudoviruses (clade1a: LYRa3, SHC014; clade3: Khosta-2). The inventors have expressed the stabilized trimeric RBD 30 derivatives (as depicted in SEQ ID NO: 13 without TPA signal, SEQ ID NO: 18 without TPA signal, SEQ ID NO: 23 without TPA signal, SEQ ID NO: 28 without 46 TPA signal, and SEQ ID NO: 33 without TPA signal), in mammalian cells (recombinant host cell) and reported good purification yields. The stabilized RBD derivatives (as depicted in SEQ ID NO: 13 without TPA signal, SEQ ID NO: 18 without TPA signal, SEQ ID NO: 23 without TPA signal, SEQ ID NO: 28 without 5 TPA signal, and SEQ ID NO: 33 without TPA signal) showed significant enhancement in the apparent melting temperature and short-term thermal tolerance than WT RBDs. All the stabilized RBDs resulted in high IgG titres in mice in individual and cocktail format and thus proved to be highly immunogenic. Stabilized trimeric RBD derivatives as depicted in SEQ ID NO: 15, SEQ ID NO: 10 20, SEQ ID NO: 25, SEQ ID NO: 30, and SEQ ID NO: 35 would also achieve similar results. The RBD cocktail formulation (having immunogenic polypeptides as depicted in SEQ ID NO: 13 without TPA signal, SEQ ID NO: 18 without TPA signal, SEQ ID NO: 23 without TPA signal, SEQ ID NO: 28 without TPA signal, and SEQ ID NO: 33 without TPA signal) performed comparable to the individual 15 clade-matched immunogens and better in case of heterologous pseudoviral neutralization. Overall, the absence of cross-reactivity within clades appears to be evident based on the findings from pseudoviral neutralization assays following vaccination with individual RBD derivatives, underscoring the significance of exposure to a variety of antigens in order to develop a broad response, such as the 20 cocktail formulation that the present inventors have employed. It was observed that in addition to naive mice, the RBD cocktail formulation (vaccine composition) of the present disclosure demonstrates immunogenicity in SARS CoV-2 RBD pre-immunized mice as well, mirroring the present situation after COVID-19 vaccination drive. Further, the presently disclosed RBD cocktail (vaccine 25 composition) exhibited remarkable thermal stability following lyophilization for a period of upto two weeks when stored at 37°C. In summary, the results show that stabilization and production of diverse Sarbecoviruses RBD derivatives to be used as vaccine antigens is a technically feasible and scalable process. The significant improvement in yield and thermostability of immunogens by transfer of identified 30 stabilizing mutations as described, would enhance the manufacturing efficiency 47 and distribution of RBD-based vaccines for Sarbecoviruses on a global scale, addressing the pressing need for quick, widespread and equitable vaccination. Example 6: Protective efficacy of Stabilized RBD trimer and RBD-S2 5 monomer cocktail formulation (vaccine composition).
[00110] K18-hACE2 mice were immunized with SWE adjuvanted Stabilized RBD oligomer cocktail (1:1 v/v), and SWE adjuvanted RBD-S2 monomer cocktail.
[00111] The stabilized RBD oligomer cocktail included WIV-1 (SEQ ID 10 NO. 55), RaTG13 (SEQ ID NO. 56), RmYN02 (SEQ ID NO. 57), BtKY72 (SEQ ID NO. 58); 2µg/antigen; total=8µg/mouse. Stabilized RBD-S2 monomer cocktail included WIV-1 (SEQ ID NO. 61), RaTG13 (SEQ ID NO. 63), RmYN02 (SEQ ID NO. 65), BtKY72 (SEQ ID NO. 67); 2µg/antigen; total=8µg/mouse).
[00112] [00102] To compare the protective efficacy of the stabilized 15 RBD oligomer cocktail and Stabilized RBD-S2 monomer cocktail; K18-hACE2 mice (n=5/group) were immunized intramuscularly with the cocktail formulations (8µg/mouse) adjuvanted with SWE in a prime-boost regimen. These mice were challenged with heterologous SARS-CoV-1 and SARS-CoV-2 BA.5 viruses post boost immunization. 20 [00113] Figure 6 illustrates efficacy of stabilized RBD oligomer cocktail and Stabilized RBD-S2 monomer cocktail, wherein A) is a schematic representation of the immunization protocol, and (B) depicts body weight change and lung viral titres in mice post SARS-CoV-1 challenge and (C) depicts body weight change and lung viral titres in mice post SARS-CoV-2 BA.5 challenge. Stabilized RBD- 25 S2 monomer cocktail showed enhanced protective efficacy against heterologous clade 1a and clade1b Sarbecoviruses. 48 I/We Claim: 1. An immunogenic polypeptide comprising a polypeptide selected from the group consisting of: 5 a. a polypeptide having an amino acid sequence of at least 95% sequence identity to the sequence selected from SEQ ID NO: 1 or SEQ ID NO: 59, wherein the polypeptide comprises substitution mutations Y34W and P195L; b. a polypeptide having an amino acid sequence of at least 95% 10 sequence identity to the sequence as selected from SEQ ID NO: 3 or SEQ ID NO: 61, wherein the polypeptide comprises substitution mutations Y34W and P195L; c. a polypeptide having an amino acid sequence of at least 95% sequence identity to the sequence selected from SEQ ID NO: 5 or SEQ ID NO: 15 63, wherein the polypeptide comprises substitution mutations A17P, Y34W, and P196L; d. a polypeptide having an amino acid sequence of at least 95% sequence identity to the sequence selected from SEQ ID NO: 7 or SEQ ID NO: 65, wherein the polypeptide comprises substitution mutations Y34W and 20 P177L; e. a polypeptide having an amino acid sequence of at least 95% sequence identity to the sequence selected from SEQ ID NO: 9 or SEQ ID NO: 67, wherein the polypeptide comprises substitution mutations Y34W and P195L; and 25 f. a polypeptide having an amino acid sequence of at least 95% sequence identity to the sequence selected from SEQ ID NO: 85 or SEQ ID NO: 69, wherein the polypeptide comprises substitution mutations A17P, Y34W, and P196L. 2. The immunogenic polypeptide as claimed in claim 1, wherein the 30 polypeptide is having an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, 49 SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID NO: 67, and SEQ ID NO: 69. 3. The immunogenic polypeptide as claimed in claim 1, wherein the polypeptide further comprises a peptide selected from TPA signal peptide; 5 oligomerization domain; HRV3C protease cleavage site or a portion thereof; His tag; one or more linkers; or combinations thereof. 4. The immunogenic polypeptide as claimed in claim 3, wherein the oligomerization domain has an amino acid sequence as set forth in SEQ ID NO. 38. 10 5. The immunogenic polypeptide as claimed in claim 3, wherein the TPA signal peptide is having an amino acid sequence as set forth in SEQ ID NO. 36, and wherein the HRV3C protease cleavage site is having an amino acid sequence as set forth in SEQ ID NO. 40. 6. The immunogenic polypeptide as claimed in claim 3, wherein the linker has 15 an amino acid sequence selected from “AAS”, “S”, “AS”, “GT”,"GSAGS", and/or "GS". 7. The immunogenic polypeptide as claimed in claim 3, wherein the polypeptide has an amino acid sequence selected from the group consisting of SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 23, 20 SEQ ID NO: 25, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 71, SEQ ID NO: 73, SEQ ID NO: 75, SEQ ID NO: 77, SEQ ID NO: 79, and SEQ ID NO: 81. 8. A polynucleotide encoding the immunogenic polypeptide as claimed in any one of claims 1 to 7. 25 9. The polynucleotide as claimed in claim 8, wherein the polynucleotide has a nucleotide sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 14, SEQ ID NO: 19, SEQ ID NO: 24, SEQ ID NO: 29, SEQ ID NO: 34, SEQ ID NO: 60, SEQ ID NO: 62, SEQ ID NO: 64, SEQ ID NO: 66, SEQ ID NO: 68, SEQ ID NO: 70, 30 SEQ ID NO: 72, SEQ ID NO: 74, SEQ ID NO: 76, SEQ ID NO: 78, SEQ ID NO: 80, and SEQ ID NO: 82. 50 10. The polynucleotide as claimed in claim 8, wherein the polynucleotide is selected from DNA, RNA, or mRNA. 11. A recombinant vector containing the polynucleotide as claimed in any one of claims 8 to 10 operably linked to a promoter. 5 12. A recombinant host cell comprising the recombinant vector as claimed in claim 11. 13. The recombinant host cell as claimed in claim 12, wherein the host cell is a bacterial cell, yeast cell, insect cell, and mammalian cell. 14. The recombinant host cell as claimed in claim 12, wherein the bacterial cell 10 is Escherichia coli, and wherein the yeast cell is selected from the group consisting of Pichia X33, Pichia GlycoSwitch® , DSMZ 70382, GS115, KM71, KM71H, BG09, GS190, GS200, JC220, JC254, JC227, JC300-JC308, YJN165, and CBS7435, and wherein the insect cell is selected from the group consisting of Expi- Sf9®, Sf9, High Five® , Sf21, and S2, and wherein the mammalian cell is selected 15 from the group consisting of Expi293F®Expi-CHO-S®, CHO-K1, CHO-S, HEK293F® , CHOBC™, SLIM™ , SPOT™ , SP2/0 , Sp2/0- Ag14, CHO DG44, HEK 293S, HEK 293 Gnt1-/- ,HEK293-EBNA1, CHOL-NSO, and NSO. 15. A vaccine composition comprising the immunogenic polypeptide as claimed in anyone of the claims 1-7, and a pharmaceutically acceptable carrier. 20 16. The vaccine composition as claimed in claim 15, wherein the vaccine composition is a cocktail formulation comprising a combination of at least 2, at least 3, at least 4, or 5 immunogenic polypeptides of amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 18, 25 SEQ ID NO: 20, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID NO: 67, SEQ ID NO: 69, SEQ ID NO: 71, SEQ ID NO: 73, SEQ ID NO: 75, SEQ ID NO: 77, SEQ ID NO: 79, and SEQ ID NO: 81. 30 17. The vaccine composition as claimed in claim 15, wherein the pharmaceutically acceptable carrier is an adjuvant selected from an oil-in-water 51 adjuvant, a polymer and water adjuvant, a water-in-oil adjuvant, an aluminum hydroxide adjuvant, and combinations thereof. 18. A method for producing the vaccine composition as claimed in claim 15, said method comprising: (a) culturing the recombinant host cell as claimed in any one 5 of claims 12 to 14 to express the immunogenic polypeptide as claimed in any one of the claims 1-7; (b) subjecting the immunogenic polypeptide to purification; and (c) contacting the immunogenic polypeptide of step (b) with a pharmaceutically acceptable carrier, to obtain the vaccine composition. 19. A method of eliciting an immune response against Sarbecoviruses in a 10 subject, the method comprising administering the subject with an effective amount of the vaccine composition as claimed in any one of claims 15-18. 20. The method as claimed in claim 19, wherein the Sarbecovirus is selected from clade 1a, clade 1b, clade 2, or clade 3 virus. 21. The method as claimed in claim 19, wherein the Sarbecovirus is selected 15 from the group consisting of SARS-CoV-1 (clade 1a), WIV-1 (clade 1a), SARS- CoV-2(clade 1b), RaTG13 (clade 1b), RmYN02 (clade 2), and BtKY72 (clade 3). 22. The method as claimed in claim 19, wherein the vaccine composition is administered by a mode selected from the group consisting of intranasal, subcutaneous, intravenous, intra-arterial, intra-peritoneal, intramuscular, 20 intradermal, oral, dermal, and buccal. 23. A kit comprising the immunogenic polypeptide as claimed in any one of the claims 1-7; or the vaccine composition as claimed in anyone of the claims 15-18, and an instruction leaflet. 24. The method as claimed in claim 19, wherein the Sarbecovirus is selected 25 from the group consisting of SARS-CoV-1 (clade 1a), WIV-1 (clade 1a), SARS- CoV-2(clade 1b), RaTG13 (clade 1b), RmYN02 (clade 2), BtKY72 (clade 3), Pangolin_GD, RaTG13 (MN996532), Pangolin_GX-P2V (EPI_ISL_410542), SARS-CoV-1_Urbani_HP03 (AY278741), SARS-CoV-1_BJ02_HP03M (AY278487), SARS-CoV-1_HGZ8L1-A_HP03E (AY394981), SARS-CoV- 30 1_GD01_HP03L (AY278489), SARS-CoV-1_GZ-C_HP03L (AY394979), SARS-CoV-1_Sino1-11_HP03L (AY485277), SARS-CoV-1_Sin852_HP03L 52 (AY559082), SARS-CoV-1_SZ3_PC03 (AY304486), SARS-CoV- 1_SZ13_PC03 (AY304487), SARS-CoV-1_SZ1_PC03 (AY304489), SARS- CoV-1_GD03T0013_HP04 (AY525636), SARS-CoV-1_GZ0402_HP04 (AY613947), SARS-CoV-1_PC4-127_PC04 (AY613951), SARS-CoV-1_PC4- 5 137_PC04 (AY627045), SARS-CoV-1_PC4-13_PC04 (AY613948), WIV16 (KT444582), WIV1 (KF367457), Rs7327 (KY417151), LYRa11 (KF569996), Rs4231 (KY417146), RsSHC014 (KC881005), Rs4084 (KY417144), BM48-31 (NC014470), BtKY72 (KY352407), ZXC21 (MG772934), ZC45 (MG772933), JL2012 (KJ473811), Rf1 (DQ412042), HeB2013 (KJ473812), 273-2005 10 (DQ648856), Rf4092 (KY417145), YN2013 (KJ473816), RmYN02 (EPI_ISL_412977), As6526 (KY417142), Rs4237 (KY417147), Rs4081 (KY417143), Rp3 (DQ071615), 279-2005 (DQ648857), Shaanxi2011 (JX993987), Yunnan2011 (JX993988), Rs4247 (KY417148), HKU3-13 (GQ153548), HKU3-1 (DQ022305), GX2013 (KJ473815), Longquan-140 15 (KF294457), HKU3-8 (GQ153543), HuB2013 (KJ473814), Hp- BCoV_Zhejiang_2013 (KF636752), HKU1 (KF686346), OC43 (KX344031), MERS-CoV (NC_019843), Bat-CoV-GCCDC1 (MT350598), Rousettus- CoV_HKU9 (MG762674), Rc-o319 (LC556375), RacCS203 (MW251308), RshSTT182 (EPI_ISL_852604), PDF-2370, PRD-0038, RsYN04 20 (EPI_ISL_1699444), BB9904 (KR559017), Khosta-1 (MZ190137), Khosta-2 (MZ190138), and RhGB01 (MW719567). 25. The recombinant host cell as claimed in claim 12, wherein the host cell is selected from the group consisting of OPENPichia (NCYC 2543 hoc1tr), OPENPichia his4, NCYC 2543 type strain, OPENPichia pep4, OPENPichia yps1, 25 OPENPichia pep4 yps1, and OPENPichia mutS strains. 26. The vaccine composition as claimed in claim 15, wherein the vaccine composition is a lyophilized composition. 53 Date 19 October 2024 MALATHI LAKSHMIKUMARAN IN/PA-1433 Agent for the Applicant To, The Controller of Patents The Patent Office at Chennai ABSTRACT IMMUNOGENIC POLYPEPTIDES AND VACCINE COMPOSITIONS AGAINST DIVERSE SARBECOVIRUSES The present disclosure relates to immunogenic polypeptides having Sarcebovirus 5 derived stabilized receptor binding domain (RBD) fragments. The immunogenic polypeptides comprise specific stabilizing mutations at various positions on the amino acid sequence. Further, the present invention also provides vaccine compositions comprising one or more of the immunogenic polypeptides, methods and uses thereof. 10 54 ,CLAIMS:I/We Claim: 1. An immunogenic polypeptide comprising a polypeptide selected from the group consisting of: 5 a. a polypeptide having an amino acid sequence of at least 95% sequence identity to the sequence selected from SEQ ID NO: 1 or SEQ ID NO: 59, wherein the polypeptide comprises substitution mutations Y34W and P195L; b. a polypeptide having an amino acid sequence of at least 95% 10 sequence identity to the sequence as selected from SEQ ID NO: 3 or SEQ ID NO: 61, wherein the polypeptide comprises substitution mutations Y34W and P195L; c. a polypeptide having an amino acid sequence of at least 95% sequence identity to the sequence selected from SEQ ID NO: 5 or SEQ ID NO: 15 63, wherein the polypeptide comprises substitution mutations A17P, Y34W, and P196L; d. a polypeptide having an amino acid sequence of at least 95% sequence identity to the sequence selected from SEQ ID NO: 7 or SEQ ID NO: 65, wherein the polypeptide comprises substitution mutations Y34W and 20 P177L; e. a polypeptide having an amino acid sequence of at least 95% sequence identity to the sequence selected from SEQ ID NO: 9 or SEQ ID NO: 67, wherein the polypeptide comprises substitution mutations Y34W and P195L; and 25 f. a polypeptide having an amino acid sequence of at least 95% sequence identity to the sequence selected from SEQ ID NO: 85 or SEQ ID NO: 69, wherein the polypeptide comprises substitution mutations A17P, Y34W, and P196L. 2. The immunogenic polypeptide as claimed in claim 1, wherein the 30 polypeptide is having an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID NO: 67, and SEQ ID NO: 69. 3. The immunogenic polypeptide as claimed in claim 1, wherein the polypeptide further comprises a peptide selected from TPA signal peptide; 5 oligomerization domain; HRV3C protease cleavage site or a portion thereof; His tag; one or more linkers; or combinations thereof. 4. The immunogenic polypeptide as claimed in claim 3, wherein the oligomerization domain has an amino acid sequence as set forth in SEQ ID NO. 38. 10 5. The immunogenic polypeptide as claimed in claim 3, wherein the TPA signal peptide is having an amino acid sequence as set forth in SEQ ID NO. 36, and wherein the HRV3C protease cleavage site is having an amino acid sequence as set forth in SEQ ID NO. 40. 6. The immunogenic polypeptide as claimed in claim 3, wherein the linker has 15 an amino acid sequence selected from “AAS”, “S”, “AS”, “GT”,"GSAGS", and/or "GS". 7. The immunogenic polypeptide as claimed in claim 3, wherein the polypeptide has an amino acid sequence selected from the group consisting of SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 23, 20 SEQ ID NO: 25, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 71, SEQ ID NO: 73, SEQ ID NO: 75, SEQ ID NO: 77, SEQ ID NO: 79, and SEQ ID NO: 81. 8. A polynucleotide encoding the immunogenic polypeptide as claimed in any one of claims 1 to 7. 25 9. The polynucleotide as claimed in claim 8, wherein the polynucleotide has a nucleotide sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 14, SEQ ID NO: 19, SEQ ID NO: 24, SEQ ID NO: 29, SEQ ID NO: 34, SEQ ID NO: 60, SEQ ID NO: 62, SEQ ID NO: 64, SEQ ID NO: 66, SEQ ID NO: 68, SEQ ID NO: 70, 30 SEQ ID NO: 72, SEQ ID NO: 74, SEQ ID NO: 76, SEQ ID NO: 78, SEQ ID NO: 80, and SEQ ID NO: 82. 10. The polynucleotide as claimed in claim 8, wherein the polynucleotide is selected from DNA, RNA, or mRNA. 11. A recombinant vector containing the polynucleotide as claimed in any one of claims 8 to 10 operably linked to a promoter. 5 12. A recombinant host cell comprising the recombinant vector as claimed in claim 11. 13. The recombinant host cell as claimed in claim 12, wherein the host cell is a bacterial cell, yeast cell, insect cell, and mammalian cell. 14. The recombinant host cell as claimed in claim 12, wherein the bacterial cell 10 is Escherichia coli, and wherein the yeast cell is selected from the group consisting of Pichia X33, Pichia GlycoSwitch® , DSMZ 70382, GS115, KM71, KM71H, BG09, GS190, GS200, JC220, JC254, JC227, JC300-JC308, YJN165, and CBS7435, and wherein the insect cell is selected from the group consisting of Expi- Sf9®, Sf9, High Five® , Sf21, and S2, and wherein the mammalian cell is selected 15 from the group consisting of Expi293F®Expi-CHO-S®, CHO-K1, CHO-S, HEK293F® , CHOBC™, SLIM™ , SPOT™ , SP2/0 , Sp2/0- Ag14, CHO DG44, HEK 293S, HEK 293 Gnt1-/- ,HEK293-EBNA1, CHOL-NSO, and NSO. 15. A vaccine composition comprising the immunogenic polypeptide as claimed in anyone of the claims 1-7, and a pharmaceutically acceptable carrier. 20 16. The vaccine composition as claimed in claim 15, wherein the vaccine composition is a cocktail formulation comprising a combination of at least 2, at least 3, at least 4, or 5 immunogenic polypeptides of amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 18, 25 SEQ ID NO: 20, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID NO: 67, SEQ ID NO: 69, SEQ ID NO: 71, SEQ ID NO: 73, SEQ ID NO: 75, SEQ ID NO: 77, SEQ ID NO: 79, and SEQ ID NO: 81. 30 17. The vaccine composition as claimed in claim 15, wherein the pharmaceutically acceptable carrier is an adjuvant selected from an oil-in-water adjuvant, a polymer and water adjuvant, a water-in-oil adjuvant, an aluminum hydroxide adjuvant, and combinations thereof. 18. A method for producing the vaccine composition as claimed in claim 15, said method comprising: (a) culturing the recombinant host cell as claimed in any one 5 of claims 12 to 14 to express the immunogenic polypeptide as claimed in any one of the claims 1-7; (b) subjecting the immunogenic polypeptide to purification; and (c) contacting the immunogenic polypeptide of step (b) with a pharmaceutically acceptable carrier, to obtain the vaccine composition. 19. A method of eliciting an immune response against Sarbecoviruses in a 10 subject, the method comprising administering the subject with an effective amount of the vaccine composition as claimed in any one of claims 15-18. 20. The method as claimed in claim 19, wherein the Sarbecovirus is selected from clade 1a, clade 1b, clade 2, or clade 3 virus. 21. The method as claimed in claim 19, wherein the Sarbecovirus is selected 15 from the group consisting of SARS-CoV-1 (clade 1a), WIV-1 (clade 1a), SARS- CoV-2(clade 1b), RaTG13 (clade 1b), RmYN02 (clade 2), and BtKY72 (clade 3). 22. The method as claimed in claim 19, wherein the vaccine composition is administered by a mode selected from the group consisting of intranasal, subcutaneous, intravenous, intra-arterial, intra-peritoneal, intramuscular, 20 intradermal, oral, dermal, and buccal. 23. A kit comprising the immunogenic polypeptide as claimed in any one of the claims 1-7; or the vaccine composition as claimed in anyone of the claims 15-18, and an instruction leaflet. 24. The method as claimed in claim 19, wherein the Sarbecovirus is selected 25 from the group consisting of SARS-CoV-1 (clade 1a), WIV-1 (clade 1a), SARS- CoV-2(clade 1b), RaTG13 (clade 1b), RmYN02 (clade 2), BtKY72 (clade 3), Pangolin_GD, RaTG13 (MN996532), Pangolin_GX-P2V (EPI_ISL_410542), SARS-CoV-1_Urbani_HP03 (AY278741), SARS-CoV-1_BJ02_HP03M (AY278487), SARS-CoV-1_HGZ8L1-A_HP03E (AY394981), SARS-CoV- 30 1_GD01_HP03L (AY278489), SARS-CoV-1_GZ-C_HP03L (AY394979), SARS-CoV-1_Sino1-11_HP03L (AY485277), SARS-CoV-1_Sin852_HP03L (AY559082), SARS-CoV-1_SZ3_PC03 (AY304486), SARS-CoV- 1_SZ13_PC03 (AY304487), SARS-CoV-1_SZ1_PC03 (AY304489), SARS- CoV-1_GD03T0013_HP04 (AY525636), SARS-CoV-1_GZ0402_HP04 (AY613947), SARS-CoV-1_PC4-127_PC04 (AY613951), SARS-CoV-1_PC4- 5 137_PC04 (AY627045), SARS-CoV-1_PC4-13_PC04 (AY613948), WIV16 (KT444582), WIV1 (KF367457), Rs7327 (KY417151), LYRa11 (KF569996), Rs4231 (KY417146), RsSHC014 (KC881005), Rs4084 (KY417144), BM48-31 (NC014470), BtKY72 (KY352407), ZXC21 (MG772934), ZC45 (MG772933), JL2012 (KJ473811), Rf1 (DQ412042), HeB2013 (KJ473812), 273-2005 10 (DQ648856), Rf4092 (KY417145), YN2013 (KJ473816), RmYN02 (EPI_ISL_412977), As6526 (KY417142), Rs4237 (KY417147), Rs4081 (KY417143), Rp3 (DQ071615), 279-2005 (DQ648857), Shaanxi2011 (JX993987), Yunnan2011 (JX993988), Rs4247 (KY417148), HKU3-13 (GQ153548), HKU3-1 (DQ022305), GX2013 (KJ473815), Longquan-140 15 (KF294457), HKU3-8 (GQ153543), HuB2013 (KJ473814), Hp- BCoV_Zhejiang_2013 (KF636752), HKU1 (KF686346), OC43 (KX344031), MERS-CoV (NC_019843), Bat-CoV-GCCDC1 (MT350598), Rousettus- CoV_HKU9 (MG762674), Rc-o319 (LC556375), RacCS203 (MW251308), RshSTT182 (EPI_ISL_852604), PDF-2370, PRD-0038, RsYN04 20 (EPI_ISL_1699444), BB9904 (KR559017), Khosta-1 (MZ190137), Khosta-2 (MZ190138), and RhGB01 (MW719567). 25. The recombinant host cell as claimed in claim 12, wherein the host cell is selected from the group consisting of OPENPichia (NCYC 2543 hoc1tr), OPENPichia his4, NCYC 2543 type strain, OPENPichia pep4, OPENPichia yps1, 25 OPENPichia pep4 yps1, and OPENPichia mutS strains. 26. The vaccine composition as claimed in claim 15, wherein the vaccine composition is a lyophilized composition.